Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Bühler A; Wolbers M; Model F; Wang Q; Belachew S; Manfrini M; Lorscheider J; Kappos L; Beyersmann J. Multiple sclerosis (Houndmills, Basingstoke, England). 2023.Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
Woelfle T; Pless S; Reyes O; Wiencierz A; Feinstein A; Calabrese P; Gugleta K; Kappos L; Lorscheider J; Naegelin Y. Journal of Neurology. 2023.A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects.
Rahmanzadeh R; Weigel M; Lu PJ; Melie-Garcia L; Nguyen TD; Cagol A; La Rosa F; Barakovic M; Lutti A; Wang Y; Bach Cuadra M; Radue EW; Gaetano L; Kappos L; Kuhle J; Magon S; Granziera C. NeuroImage. Clinical. 2022.A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.
Rahmanzadeh R; Galbusera R; Lu PJ; Bahn E; Weigel M; Barakovic M; Franz J; Nguyen TD; Spincemaille P; Schiavi S; Daducci A; La Rosa F; Absinta M; Sati P; Bach Cuadra M; Radue EW; Leppert D; Kuhle J; Kappos L; Brück W; Reich DS; Stadelmann C; Wang Y; Granziera C. Annals of neurology. 2022.Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.
Cagol A; Schaedelin S; Barakovic M; Benkert P; Todea RA; Rahmanzadeh R; Galbusera R; Lu PJ; Weigel M; Melie-Garcia L; Ruberte E; Siebenborn N; Battaglini M; Radue EW; Yaldizli Ö; Oechtering J; Sinnecker T; Lorscheider J; Fischer-Barnicol B; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Chan A; Salmen A; Pot C; Bridel C; Zecca C; Derfuss T; Lieb JM; Remonda L; Wagner F; Vargas MI; Du Pasquier R; Lalive PH; Pravatà E; Weber J; Cattin PC; Gobbi C; Leppert D; Kappos L; Kuhle J; Granziera C. JAMA neurology. 2022.Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring D; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J. Neurology. 2022.Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J. Neurology. 2022.Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J; Cortese M; Edan G; Freedman MS; Hartung HP; Montalbán X; Sandbrink R; Radü EW; Barkhof F; Wicklein EM; Kappos L; Ascherio A; Munger KL. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Brain atrophy measurement over a MRI scanner change in multiple sclerosis.
Sinnecker T; Schädelin S; Benkert P; Ruberte E; Amann M; Lieb JM; Naegelin Y; Müller J; Kuhle J; Derfuss T; Kappos L; Wuerfel J; Granziera C; Yaldizli Ö. NeuroImage. Clinical. 2022.Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography.
Schiavi S; Lu PJ; Weigel M; Lutti A; Jones DK; Kappos L; Granziera C; Daducci A. NeuroImage. 2022.Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome.
Zandl-Lang M; Züllig T; Trötzmüller M; Naegelin Y; Abela L; Wilken B; Scholl-Buergi S; Karall D; Kappos L; Köfeler H; Plecko B. Metabolites. 2022.Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis.
Müller J; Sinnecker T; Wendebourg MJ; Schläger R; Kuhle J; Schädelin S; Benkert P; Derfuss T; Cattin P; Jud C; Spiess F; Amann M; Lincke T; Barakovic M; Cagol A; Tsagkas C; Parmar K; Pröbstel AK; Reimann S; Asseyer S; Duchow A; Brandt A; Ruprecht K; Hadjikhani N; Fukumoto S; Watanabe M; Masaki K; Matsushita T; Isobe N; Kira JI; Kappos L; Würfel J; Granziera C; Paul F; Yaldizli Ö. Neurology(R) neuroimmunology & neuroinflammation. 2022.Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Sharmin S; Bovis F; Malpas C; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Terzi M; Gerlach O; Alroughani R; Boz C; Shaygannejad V; van Pesch V; Cartechini E; Kappos L; Lechner-Scott J; Bergamaschi R; Turkoglu R; Solaro C; Iuliano G; Granella F; Van Wijmeersch B; Spitaleri D; Slee M; McCombe P; Prevost J; Ampapa R; Ozakbas S; Sanchez-Menoyo JL; Soysal A; Vucic S; Petersen T; de Gans K; Butler E; Hodgkinson S; Sidhom Y; Gouider R; Cristiano E; Castillo-Triviño T; Saladino ML; Barnett M; Moore F; Rozsa C; Yamout B; Skibina O; van der Walt A; Buzzard K; Gray O; Hughes S; Sempere AP; Singhal B; Fragoso Y; Shaw C; Kermode A; Taylor B; Simo M; Shuey N; Al-Harbi T; Macdonell R; Dominguez JA; Csepany T; Sirbu CA; Sormani MP; Butzkueven H; Kalincik T. European journal of neurology. 2022.Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].
De Brouwer E; Becker T; Moreau Y; Havrdova EK; Trojano M; Eichau S; Ozakbas S; Onofrj M; Grammond P; Kuhle J; Kappos L; Sola P; Cartechini E; Lechner-Scott J; Alroughani R; Gerlach O; Kalincik T; Granella F; Grand'Maison F; Bergamaschi R; Sá MJ; Van Wijmeersch B; Soysal A; Sanchez-Menoyo JL; Solaro C; Boz C; Iuliano G; Buzzard K; Aguera-Morales E; Terzi M; Trivio TC; Spitaleri D; Van Pesch V; Shaygannejad V; Moore F; Oreja-Guevara C; Maimone D; Gouider R; Csepany T; Ramo-Tello C; Peeters L. . 2022.Development and implementation of new diagnostic technologies in neurology.
Granziera C; Woelfle T; Kappos L. Nature reviews. Neurology. 2022.Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'Maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; Macdonell RA; Aguera-Morales E; Cabre P; Ben NH; Van der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; de Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T; MSBase and OFSEP. Neurology. 2022.Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ; EXPAND Clinical Investigators. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.
Nakamura K; Mokliatchouk O; Arnold DL; Yousry TA; Kappos L; Richert N; Ayling-Rouse K; Miller C; Fisher E. Frontiers in neurology. 2022.Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
Sprenger T; Kappos L; Sormani MP; Miller AE; Poole EM; Cavalier S; Wuerfel J. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J; Hauser SL; Bar-Or A; Montalban X; Cohen JA; Cross AH; Deiva K; Ganjgahi H; Häring DA; Li B; Pingili R; Ramanathan K; Su W; Willi R; Kieseier B; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Battaglini M; Vrenken H; Tappa Brocci R; Gentile G; Luchetti L; Versteeg A; Freedman MS; Uitdehaag BMJ; Kappos L; Comi G; Seitzinger A; Jack D; Sormani MP; Barkhof F; De Stefano N. European journal of neurology. 2022.High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
Diebold M.; Galli E.; Kopf A.; Sanderson N.S.R.; Callegari I.; Benkert P.; Nunez N.G.; Ingelfinger F.; Herms S.; Cichon S.; Kappos L.; Kuhle J.; Becher B.; Claassen M.; Derfuss T.. Proceedings of the National Academy of Sciences of the United States of America. 2022.Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold M; Galli E; Kopf A; Sanderson N; Callegari I; Ingelfinger F; Núñez NG; Benkert P; Kappos L; Kuhle J; Becher B; Claassen M; Derfuss T. Annals of neurology. 2022.Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.
Lam KH; van Munster CEP; D'Souza M; Steinheimer S; Kamm CP; Burggraaff J; Johnson M; Zaykov Y; Dorn J; Dahlke F; Kappos L; Killestein J; Uitdehaag B. International journal of MS care. 2022.Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS.
Oechtering J; Lincke T; Schaedelin S; Décard BF; Maceski A; Orleth A; Meier S; Willemse E; Buchmann A; Khalil M; Derfuss T; Benkert P; Heijnen I; Regeniter A; Müller S; Achtnichts L; Lalive P; Salmen A; Pot C; Gobbi C; Kappos L; Granziera C; Leppert D; Schlaeger R; Lieb JM; Kuhle J; Swiss MS Cohort Study. Annals of neurology. 2022.Longitudinal changes of deep gray matter shape in multiple sclerosis.
Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S. NeuroImage. Clinical. 2022.Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
Gold R.; Arnold D.L.; Bar-Or A.; Fox R.J.; Kappos L.; Mokliatchouk O.; Jiang X.; Lyons J.; Kapadia S.; Miller C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA; Selmaj KW; Steinman L; Comi G; Bar-Or A; Arnold DL; Hartung HP; Montalbán X; Havrdová EK; Sheffield JK; Minton N; Cheng CY; Silva D; Kappos L; Cohen JA. . 2022.Microstructure-Weighted Connectomics in Multiple Sclerosis.
Bosticardo S; Schiavi S; Schaedelin S; Lu PJ; Barakovic M; Weigel M; Kappos L; Kuhle J; Daducci A; Granziera C. Brain connectivity. 2022.Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Malpas CB; Roos I; Sharmin S; Buzzard K; Skibina O; Butzkueven H; Kappos L; Patti F; Alroughani R; Horakova D; Havrdova EK; Izquierdo G; Eichau S; Hodgkinson S; Grammond P; Lechner-Scott J; Kalincik T; MSBase Study Group. Clinical drug investigation. 2022.Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Kalincik T; Kister I; Bacon TE; Malpas CB; Sharmin S; Horakova D; Kubala-Havrdova E; Patti F; Izquierdo G; Eichau S; Ozakbas S; Onofrj M; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Boz C; Grand'Maison F; Bergamaschi R; Gerlach O; Sa MJ; Kappos L; Cartechini E; Lechner-Scott J; van Pesch V; Shaygannejad V; Granella F; Spitaleri D; Iuliano G; Maimone D; Prevost J; Soysal A; Turkoglu R; Ampapa R; Butzkueven H; Cutter G; for MSBase Study Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I; Kappos L; Giovannoni G; Calabresi PA; Sandrock A; Cheng W; Xiao S; Riester K; Belachew S; Deykin A; Zhu B. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Meaton I; Altokhis A; Allen CM; Clarke MA; Sinnecker T; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Granziera C; Kappos L; Montalban X; Rovira À; Wuerfel J; Evangelou N. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials.
Hardmeier M; Schlaeger R; Lascano AM; Toffolet L; Schindler C; Gobbi C; Lalive P; Kuhle J; Kappos L; Fuhr P. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2022.Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials.
Ziemssen T; Arnold DL; Alvarez E; Cross AH; Willi R; Li B; Kukkaro P; Kropshofer H; Ramanathan K; Merschhemke M; Kieseier B; Su W; Häring DA; Hauser SL; Kappos L; Kuhle J. Frontiers in immunology. 2022.Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Kropshofer H; Häring DA; Kappos L; Leppert D; Kuhle J. . 2022.Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T. Acta Neuropathologica. 2022.Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.
Parmar K; Fonov VS; Naegelin Y; Amann M; Wuerfel J; Collins DL; Gaetano L; Magon S; Sprenger T; Kappos L; Granziera C; Tsagkas C. Cerebellum (London, England). 2022.Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
Giovannoni G.; Kappos L.; de Seze J.; Hauser S.L.; Overell J.; Koendgen H.; Manfrini M.; Wang Q.; Wolinsky J.S.. European journal of neurology. 2022.Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
Butzkueven H.; Spelman T.; Horakova D.; Hughes S.; Solaro C.; Izquierdo G.; Kubala Havrdova E.; Grand'Maison F.; Prat A.; Girard M.; Hupperts R.; Onofrj M.; Lugaresi A.; Taylor B.; Giovannoni G.; Kappos L.; Hauser S.L.; Montalban X.; Craveiro L.; Freitas R.; Model F.; Overell J.; Muros-Le Rouzic E.; Sauter A.; Wang Q.; Wormser D.; Wolinsky J.S.. European journal of neurology. 2022.Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. The Lancet Neurology. 2022.Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
Lokhande H.; Rosso M.; Tauhid S.; Chu R.; Healy B.C.; Saxena S.; Barro C.; Paul A.; Polgar-Turcsanyi M.; Anderson M.; Glanz B.I.; Kropshofer H.; Granziera C.; Leppert D.; Kappos L.; Kuhle J.; Weiner H.L.; Bakshi R.; Chitnis T.. Multiple sclerosis journal - experimental, translational and clinical. 2022.Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC. Journal of Neurology. 2022.Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome
Wendebourg M.J.; Weigel M.; Richter L.; Gocheva V.; Hafner P.; Orsini A.-L.; Crepulja V.; Schmidt S.; Huck A.; Oechtering J.; Blatow M.; Haas T.; Granziera C.; Kappos L.; Cattin P.; Bieri O.; Fischer D.; Schlaeger R.. European journal of neurology. 2022.Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Kuhle J; Daizadeh N; Benkert P; Maceski A; Barro C; Michalak Z; Sormani MP; Godin J; Shankara S; Samad TA; Jacobs A; Chung L; Rӧsch N; Kaiser C; Mitchell CP; Leppert D; Havari E; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
Tur C; Dubessy AL; Otero-Romero S; Amato MP; Derfuss T; Di Pauli F; Iacobaeus E; Mycko M; Abboud H; Achiron A; Bellinvia A; Boyko A; Casanova JL; Clifford D; Dobson R; Farez MF; Filippi M; Fitzgerald KC; Fonderico M; Gouider R; Hacohen Y; Hellwig K; Hemmer B; Kappos L; Ladeira F; Lebrun-Frénay C; Louapre C; Magyari M; Mehling M; Oreja-Guevara C; Pandit L; Papeix C; Piehl F; Portaccio E; Ruiz-Camps I; Selmaj K; Simpson-Yap S; Siva A; Sorensen PS; Sormani MP; Trojano M; Vaknin-Dembinsky A; Vukusic S; Weinshenker B; Wiendl H; Winkelmann A; Zuluaga Rodas MI; Tintoré M; Stankoff B. Multiple sclerosis (Houndmills, Basingstoke, England). 2022.The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.
Mattiesing RM; Gentile G; Brouwer I; van Schijndel RA; Uitdehaag BMJ; Twisk JWR; Kappos L; Freedman MS; Comi G; Jack D; De Stefano N; Barkhof F; Battaglini M; Vrenken H. NeuroImage. Clinical. 2022.2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.
Wattjes MP; Ciccarelli O; Reich DS; Banwell B; de Stefano N; Enzinger C; Fazekas F; Filippi M; Frederiksen J; Gasperini C; Hacohen Y; Kappos L; Li DKB; Mankad K; Montalban X; Newsome SD; Oh J; Palace J; Rocca MA; Sastre-Garriga J; Tintoré M; Traboulsee A; Vrenken H; Yousry T; Barkhof F; Rovira À; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. The Lancet Neurology. 2021.Additive and interaction effects of working memory and motor sequence training on brain functional connectivity.
Zuber P; Gaetano L; Griffa A; Huerbin M; Pedullà L; Bonzano L; Altermatt A; Tsagkas C; Parmar K; Hagmann P; Wuerfel J; Kappos L; Sprenger T; Sporns O; Magon S. Scientific Reports. 2021.Artificial intelligence extension of the OSCAR-IB criteria.
Petzold A; Albrecht P; Balcer L; Bekkers E; Brandt AU; Calabresi PA; Deborah OG; Graves JS; Green A; Keane PA; Nij Bijvank JA; Sander JW; Paul F; Saidha S; Villoslada P; Wagner SK; Yeh EA; IMSVISUAL, ERN-EYE Consortium.. Annals of Clinical and Translational Neurology. 2021.Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
Langdon DW; Tomic D; Penner IK; Calabrese P; Cutter G; Häring DA; Dahlke F; Kappos L. European journal of neurology. 2021.Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).
Collongues N; Kuhle J; Tsagkas C; Lamy J; Meyer N; Barro C; Parmar K; Amann M; Wuerfel J; Kappos L; Moreau T; de Seze J. Brain and Behavior. 2021.Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K. European journal of neurology. 2021.Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C. Neurology. 2021.Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance.
Tsagkas C; Parmar K; Pezold S; Barro C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Papadopoulou A; Wuerfel J; Kappos L; Kuhle J; Sprenger T; Granziera C; Magon S. Human brain mapping. 2021.Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP)
Butzkueven H.; Trojano M.; Kappos L.; Spelman T.; Wiendl H.; Rosales K.; Su R.; Licata S.; Ho P.-R.; Campbell N.. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
Fischer-Barnicol B.; Oechtering J.; Kuhle J.; Lorscheider J.; Kappos L.; Derfuss T.. Neurology-Neuroimmunology & Neuroinflammation. 2021.Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Journal of Neurology. 2021.Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study.
Francalancia J; Mavrogiorgou P; Juckel G; Mitrovic T; Kuhle J; Naegelin Y; Kappos L; Calabrese P. Brain sciences. 2021.Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis.
Chalkou K; Steyerberg E; Bossuyt P; Subramaniam S; Benkert P; Kuhle J; Disanto G; Kappos L; Zecca C; Egger M; Salanti G. Diagnostic and prognostic research. 2021.Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references
de Sitter A.; Burggraaff J.; Bartel F.; Palotai M.; Liu Y.; Simoes J.; Ruggieri S.; Schregel K.; Ropele S.; Rocca M.A.; Gasperini C.; Gallo A.; Schoonheim M.M.; Amann M.; Yiannakas M.; Pareto D.; Wattjes M.P.; Sastre-Garriga J.; Kappos L.; Filippi M.; Enzinger C.; Frederiksen J.; Uitdehaag B.; Guttmann C.R.G.; Barkhof F.; Vrenken H.. NeuroImage-Clinical. 2021.Diagnosis of Progressive Multiple Sclerosis from the Imaging Perspective: A Review
Filippi M.; Preziosa P.; Barkhof F.; Chard D.T.; De Stefano N.; Fox R.J.; Gasperini C.; Kappos L.; Montalban X.; Moraal B.; Reich D.S.; Rovira A.; Toosy A.T.; Traboulsee A.; Weinshenker B.G.; Zeydan B.; Banwell B.L.; Rocca M.A.. JAMA neurology. 2021.Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Cree BA; Cohen JA; Reder AT; Tomic D; Silva D; Piani Meier D; Laflamme AK; Ritter S; Leppert D; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
Centonze D.; Rocca M.A.; Gasperini C.; Kappos L.; Hartung H.-P.; Magyari M.; Oreja-Guevara C.; Trojano M.; Wiendl H.; Filippi M.. Journal of Neurology. 2021.Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
DeLuca J; Schippling S; Montalban X; Kappos L; Cree BAC; Comi G; Arnold DL; Hartung HP; Sheffield JK; Liu H; Silva D; Cohen JA. Multiple sclerosis and related disorders. 2021.Fingolimod in children with Rett syndrome: the FINGORETT study.
Naegelin Y; Kuhle J; Schädelin S; Datta AN; Magon S; Amann M; Barro C; Ramelli GP; Heesom K; Barde YA; Weber P; Kappos L. Orphanet Journal of Rare Diseases. 2021.GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology.
Lu PJ; Yoo Y; Rahmanzadeh R; Galbusera R; Weigel M; Ceccaldi P; Nguyen TD; Spincemaille P; Wang Y; Daducci A; La Rosa F; Bach Cuadra M; Sandkühler R; Nael K; Doshi A; Fayad ZA; Kuhle J; Kappos L; Odry B; Cattin P; Gibson E; Granziera C. NeuroImage. Clinical. 2021.GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation.
Lu PJ; Barakovic M; Weigel M; Rahmanzadeh R; Galbusera R; Schiavi S; Daducci A; La Rosa F; Bach Cuadra M; Sandkühler R; Kuhle J; Kappos L; Cattin P; Granziera C. Frontiers in neuroscience. 2021.Imaging multiple sclerosis pathology at 160 μm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3 T
Weigel M.; Dechent P.; Galbusera R.; Bahn E.; Nair G.; Lu P.-J.; Kappos L.; Bruck W.; Stadelmann C.; Granziera C.. Scientific Reports. 2021.Impact of complement activation on clinical outcomes in multiple sclerosis.
Keller CW; Oechtering J; Wiendl H; Kappos L; Kuhle J; Lünemann JD. Annals of Clinical and Translational Neurology. 2021.Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.
Oechtering J; Schaedelin S; Benkert P; Müller S; Achtnichts L; Vehoff J; Disanto G; Findling O; Fischer-Barnicol B; Orleth A; Chan A; Pot C; Barakovic M; Rahmanzadeh R; Galbusera R; Heijnen I; Lalive PH; Wuerfel J; Subramaniam S; Aeschbacher S; Conen D; Naegelin Y; Maceski A; Meier S; Berger K; Wiendl H; Lincke T; Lieb J; Yaldizli Ö; Sinnecker T; Derfuss T; Regeniter A; Zecca C; Gobbi C; Kappos L; Granziera C; Leppert D; Kuhle J; Swiss Multiple Sclerosis Cohort Study. Annals of neurology. 2021.Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.
De Brouwer E; Becker T; Moreau Y; Havrdova EK; Trojano M; Eichau S; Ozakbas S; Onofrj M; Grammond P; Kuhle J; Kappos L; Sola P; Cartechini E; Lechner-Scott J; Alroughani R; Gerlach O; Kalincik T; Granella F; Grand'Maison F; Bergamaschi R; José Sá M; Van Wijmeersch B; Soysal A; Sanchez-Menoyo JL; Solaro C; Boz C; Iuliano G; Buzzard K; Aguera-Morales E; Terzi M; Trivio TC; Spitaleri D; Van Pesch V; Shaygannejad V; Moore F; Oreja-Guevara C; Maimone D; Gouider R; Csepany T; Ramo-Tello C; Peeters L. Computer methods and programs in biomedicine. 2021.MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a.
Sormani MP; Freedman MS; Aldridge J; Marhardt K; Kappos L; De Stefano N. Multiple sclerosis and related disorders. 2021.Measuring treatment response to advance precision medicine for multiple sclerosis.
Calabresi PA; Kappos L; Giovannoni G; Plavina T; Koulinska I; Edwards MR; Kieseier B; de Moor C; Sotirchos ES; Fisher E; Rudick RA; Sandrock A. Annals of Clinical and Translational Neurology. 2021.Mind the gap: from neurons to networks to outcomes in multiple sclerosis.
Chard DT; Alahmadi AAS; Audoin B; Charalambous T; Enzinger C; Hulst HE; Rocca MA; Rovira À; Sastre-Garriga J; Schoonheim MM; Tijms B; Tur C; Gandini Wheeler-Kingshott CAM; Wink AM; Ciccarelli O; Barkhof F; MAGNIMS Study Group.. Nature reviews. Neurology. 2021.Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging.
Rahmanzadeh R; Lu PJ; Barakovic M; Weigel M; Maggi P; Nguyen TD; Schiavi S; Daducci A; La Rosa F; Schaedelin S; Absinta M; Reich DS; Sati P; Wang Y; Bach Cuadra M; Radue EW; Kuhle J; Kappos L; Granziera C. Brain : a journal of neurology. 2021.No consensus about consensus?
Kappos L. . 2021.No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
Butzkueven H; Kappos L; Spelman T; Trojano M; Wiendl H; Su R; Liao S; Hyde R; Licata S; Ho PR; Campbell N. Therapeutic advances in neurological disorders. 2021.Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
Gibiansky E.; Petry C.; Mercier F.; Gunther A.; Herman A.; Kappos L.; Hauser S.; Yamamoto Y.; Wang Q.; Model F.; Kletzl H.. British journal of clinical pharmacology. 2021.Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program
Selmaj K.W.; Cohen J.A.; Comi G.; Bar-Or A.; Arnold D.L.; Steinman L.; Hartung H.P.; Montalban X.; Havrdova E.K.; Cree B.A.C.; Minton N.; Sheffield J.K.; Ding N.; Kappos L.. Multiple sclerosis and related disorders. 2021.Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
Harris S.; Comi G.; Cree B.A.C.; Arnold D.L.; Steinman L.; Sheffield J.K.; Southworth H.; Kappos L.; Cohen J.A.. European journal of neurology. 2021.Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial
Kappos L.; Fox R.J.; Burcklen M.; Freedman M.S.; Havrdova E.K.; Hennessy B.; Hohlfeld R.; Lublin F.; Montalban X.; Pozzilli C.; Scherz T.; D'Ambrosio D.; Linscheid P.; Vaclavkova A.; Pirozek-Lawniczek M.; Kracker H.; Sprenger T.. JAMA neurology. 2021.Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study.
Woelfle T; Pless S; Wiencierz A; Kappos L; Naegelin Y; Lorscheider J. Journal of medical Internet research. 2021.Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19.
Fuchs V; Kutza M; Wischnewski S; Deigendesch N; Lutz L; Kulsvehagen L; Ricken G; Kappos L; Tzankov A; Hametner S; Frank S; Schirmer L; Pröbstel AK. Neurology(R) neuroimmunology & neuroinflammation. 2021.Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer.
Lukas C; Bellenberg B; Prados F; Valsasina P; Parmar K; Brouwer I; Pareto D; Rovira À; Sastre-Garriga J; Gandini Wheeler-Kingshott CAM; Kappos L; Rocca MA; Filippi M; Yiannakas M; Barkhof F; Vrenken H. Frontiers in neurology. 2021.Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis
Granziera C.; Wuerfel J.; Barkhof F.; Calabrese M.; De Stefano N.; Enzinger C.; Evangelou N.; Filippi M.; Geurts J.J.G.; Reich D.S.; Rocca M.A.; Ropele S.; Rovira A.; Sati P.; Toosy A.T.; Vrenken H.; Gandini Wheeler-Kingshott C.A.M.; Kappos L.. Brain : a journal of neurology. 2021.Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Wiendl H; Spelman T; Butzkueven H; Kappos L; Trojano M; Su R; Campbell N; Ho PR; Licata S. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
Kappos L.; Cohan S.; Arnold D.L.; Robinson R.R.; Holman J.; Fam S.; Parks B.; Xiao S.; Castro-Borrero W.. Therapeutic advances in neurological disorders. 2021.Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; TERIKIDS Investigators. The Lancet Neurology. 2021.Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
Hauser SL; Kappos L; Montalban X; Craveiro L; Chognot C; Hughes R; Koendgen H; Pasquarelli N; Pradhan A; Prajapati K; Wolinsky JS. Neurology. 2021.Serum neurofilament light chain as outcome marker for intensive care unit patients.
Fisse AL; Pitarokoili K; Leppert D; Motte J; Pedreiturria X; Kappos L; Gold R; Kuhle J; Yoon MS. Journal of Neurology. 2021.Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019.
Sutter R; Hert L; De Marchis GM; Twerenbold R; Kappos L; Naegelin Y; Kuster GM; Benkert P; Jost J; Maceski AM; Rüegg S; Siegemund M; Leppert D; Tschudin-Sutter S; Kuhle J. Annals of neurology. 2021.Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
Cree B.A.C.; Magnusson B.; Rouyrre N.; Fox R.J.; Giovannoni G.; Vermersch P.; Bar-Or A.; Gold R.; Piani Meier D.; Karlsson G.; Tomic D.; Wolf C.; Dahlke F.; Kappos L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L. Neurology. 2021.Standardization and digitization of clinical data in multiple sclerosis.
D'Souza M; Papadopoulou A; Girardey C; Kappos L. Nature reviews. Neurology. 2021.Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica
Tsagkas C.; Schafer S.; Baumgartner A.; Muller J.; Sinnecker T.; Mehling M.; van der Stouwe J.G.; Felder S.; Panagiotou A.; Potlukova E.; Winzeler B.; Scholz M.C.; Timper K.; Blackham K.; Nickel C.H.; Christ-Crain M.; Bingisser R.; Lyrer P.; Kappos L.; Yaldizli O.. The Lancet. 2021.The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
Ghezzi A; Amato MP; Edan G; Hartung HP; Havrdová EK; Kappos L; Montalban X; Pozzilli C; Sorensen PS; Trojano M; Vermersch P; Comi G. Multiple sclerosis (Houndmills, Basingstoke, England). 2021.Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L. The Lancet Neurology. 2020.Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Iacobaeus E.; Arrambide G.; Amato M.P.; Derfuss T.; Vukusic S.; Hemmer B.; Tintore M.; Brundin L.; Berger J.; Boyko A.; Brinar V.; Brownlee W.; Ciccarelli O.; Coles A.; Correale J.; Cutter G.; Edan G.; Evangelou N.; Fernandez O.; Frederiksen J.; Gold R.; Hacohen Y.; Hartung H.-P.; Hellwig K.; Hillert J.; Imitola J.; Kalincik T.; Kappos L.; Khoury S.; Kim H.J.; Havrdova E.K.; Liblau R.; Lycke J.; Montalban X.; Muraro P.; Reingold S.; Schmierer K.; Sellebjerg F.; Sorensen P.S.; Solari A.; Sormani M.P.; Thompson A.; Trapp B.; Tremlett H.; Trojano M.; Tur C.; Uccelli A.; van Pesch V.; Waubant E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Aggressive multiple sclerosis (2): Treatment
Arrambide G.; Iacobaeus E.; Amato M.P.; Derfuss T.; Vukusic S.; Hemmer B.; Brundin L.; Tintore M.; Berger J.; Boyko A.; Brinar V.; Brownlee W.; Ciccarelli O.; Coles A.; Correale J.; Cutter G.; Edan G.; Evangelou N.; Fernandez O.; Frederiksen J.; Gold R.; Hacohen Y.; Hartung H.-P.; Hellwig K.; Hillert J.; Imitola J.; Kalincik T.; Kappos L.; Khoury S.; Kim H.J.; Havrdova E.K.; Liblau R.; Lycke J.; Montalban X.; Muraro P.; Reingold S.; Schmierer K.; Sellebjerg F.; Sorensen P.S.; Solari A.; Sormani M.P.; Thompson A.; Trapp B.; Tremlett H.; Trojano M.; Tur C.; Uccelli A.; van Pesch V.; Waubant E.. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
Sprenger T.; Kappos L.; Radue E.-W.; Gaetano L.; Mueller-Lenke N.; Wuerfel J.; Poole E.M.; Cavalier S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study.
D'Souza M; Van Munster CEP; Dorn JF; Dorier A; Kamm CP; Steinheimer S; Dahlke F; Uitdehaag BMJ; Kappos L; Johnson M. Journal of Medical Internet Research. 2020.Blood neurofilament light levels segregate treatment effects in multiple sclerosis.
Delcoigne B; Manouchehrinia A; Barro C; Benkert P; Michalak Z; Kappos L; Leppert D; Tsai JA; Plavina T; Kieseier BC; Lycke J; Alfredsson L; Kockum I; Kuhle J; Olsson T; Piehl F. Neurology. 2020.Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Kappos L.; Wolinsky J.S.; Giovannoni G.; Arnold D.L.; Wang Q.; Bernasconi C.; Model F.; Koendgen H.; Manfrini M.; Belachew S.; Hauser S.L.. JAMA neurology. 2020.Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Roos I.; Leray E.; Frascoli F.; Casey R.; Brown W.J.L.; Horakova D.; Havrdova E.K.; Trojano M.; Patti F.; Izquierdo G.; Eichau S.; Onofrj M.; Lugaresi A.; Prat A.; Girard M.; Grammond P.; Sola P.; Ferraro D.; Ozakbas S.; Bergamaschi R.; Sa M.J.; Cartechini E.; Boz C.; Granella F.; Hupperts R.; Terzi M.; Lechner-Scott J.; Spitaleri D.; van Pesch V.; Soysal A.; Olascoaga J.; Prevost J.; Aguera-Morales E.; Slee M.; Csepany T.; Turkoglu R.; Sidhom Y.; Gouider R.; van Wijmeersch B.; McCombe P.; Macdonell R.; Coles A.; Malpas C.B.; Butzkueven H.; Vukusic S.; Kalincik T.; Duquette P.; Grand'Maison F.; Iuliano G.; Ramo-Tello C.; Solaro C.; Cabrera-Gomez J.A.; Rio M.E.; Bolanos R.F.; Shaygannejad V.; Oreja-Guevara C.; Sanchez-Menoyo J.L.; Petersen T.; Altintas A.; Barnett M.; Flechter S.; Fragoso Y.; Amato M.P.; Moore F.; Ampapa R.; Verheul F.; Hodgkinson S.; Cristiano E.; Yamout B.; Laureys G.; Dominguez J.A.; Zwanikken C.; Deri N.; Dobos E.; Vrech C.; Butler E.; Rozsa C.; Petkovska-Boskova T.; Karabudak R.; Rajda C.; Alkhaboori J.; Saladino M.L.; Shaw C.; Shuey N.; Vucic S.; Sempere A.P.; Campbell J.; Piroska I.; Taylor B.; van der Walt A.; Kappos L.; Roullet E.; Gray O.; Simo M.; Sirbu C.-A.; Brochet B.; Cotton F.; de Seze J.; Dion A.; Douek P.; Guillemin F.; Laplaud D.; Lebrun-Frenay C.; Moreau T.; Olaiz J.; Pelletier J.; Rigaud-Bully C.; Stankoff B.; Marignier R.; Debouverie M.; Edan G.; Ciron J.; Ruet A.; Collongues N.; Lubetzki C.; Vermersch P.; Labauge P.; Defer G.; Cohen M.; Fromont A.; Wiertlewsky S.; Berger E.; Clavelou P.; Audoin B.; Giannesini C.; Gout O.; Thouvenot E.; Heinzlef O.; Al-Khedr A.; Bourre B.; Casez O.; Cabre P.; Montcuquet A.; Creange A.; Camdessanche J.-P.; Faure J.; Maurousset A.; Patry I.; Hankiewicz K.; Pottier C.; Maubeuge N.; Labeyrie C.; Nifle C.. Brain : a journal of neurology. 2020.Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.
Zuber P; Tsagkas C; Papadopoulou A; Gaetano L; Huerbin M; Geiter E; Altermatt A; Parmar K; Ettlin T; Schuster-Amft C; Suica Z; Alrasheed H; Wuerfel J; Kesselring J; Kappos L; Sprenger T; Magon S. Journal of Neurology. 2020.Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials.
D'Souza M; Heikkilä A; Lorscheider J; Haller V; Kravalis K; Gysin S; Fuertes NAC; Fricker E; Lam E; Higgins P; Tomic D; Papadopoulou A; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes.
Todea RA; Lu PJ; Fartaria MJ; Bonnier G; Du Pasquier R; Krueger G; Bach Cuadra M; Psychogios MN; Kappos L; Kuhle J; Granziera C. Frontiers in neurology. 2020.Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.
de Sitter A; Visser M; Brouwer I; Cover KS; van Schijndel RA; Eijgelaar RS; Müller DMJ; Ropele S; Kappos L; Rovira Á; Filippi M; Enzinger C; Frederiksen J; Ciccarelli O; Guttmann CRG; Wattjes MP; Witte MG; de Witt Hamer PC; Barkhof F; Vrenken H; MAGNIMS Study Group and Alzheimer’s Disease Neuroimaging Initiative. European radiology. 2020.Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
Hauser S.L.; Kappos L.; Arnold D.L.; Bar-Or A.; Brochet B.; Naismith R.T.; Traboulsee A.; Wolinsky J.S.; Belachew S.; Koendgen H.; Levesque V.; Manfrini M.; Model F.; Hubeaux S.; Mehta L.; Montalban X.. Neurology. 2020.Growth differentiation factor 15 is increased in stable MS.
Amstad A; Coray M; Frick C; Barro C; Oechtering J; Amann M; Wischhusen J; Kappos L; Naegelin Y; Kuhle J; Mehling M. Neurology(R) neuroimmunology & neuroinflammation. 2020.Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials
Riester K.; Kappos L.; Selmaj K.; Lindborg S.; Lipkovich I.; Elkins J.. Multiple sclerosis and related disorders. 2020.Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies
Sander L.; Horvath A.; Pezold S.; Andermatt S.; Amann M.; Sinnecker T.; Wendebourg M.J.; Kesenheimer E.; Yaldizli O.; Kappos L.; Granziera C.; Wuerfel J.; Cattin P.; Schlaeger R.. Frontiers in neuroscience. 2020.Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment.
von Wyl V; Décard BF; Benkert P; Lorscheider J; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö. European journal of neurology. 2020.Laminar analysis of the cerebellar cortex shows widespread damage in early MS patients: A pilot study at 7T MRI.
Galbusera R; Parmar K; Boillat Y; Fartaria MJ; Todea AR; Brien KO; Smolinski A; Kappos L; van der Zwaag W; Granziera C. Multiple sclerosis journal - experimental, translational and clinical. 2020.Levels of brain-derived neurotrophic factor in patients with multiple sclerosis.
Naegelin Y; Saeuberli K; Schaedelin S; Dingsdale H; Magon S; Baranzini S; Amann M; Parmar K; Tsagkas C; Calabrese P; Penner IK; Kappos L; Barde YA. Annals of Clinical and Translational Neurology. 2020.Longitudinal patterns of cortical thinning in multiple sclerosis.
Tsagkas C; Chakravarty MM; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Magon S. Human brain mapping. 2020.Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Wolinsky J.S.; Arnold D.L.; Brochet B.; Hartung H.-P.; Montalban X.; Naismith R.T.; Manfrini M.; Overell J.; Koendgen H.; Sauter A.; Bennett I.; Hubeaux S.; Kappos L.; Hauser S.L.. The Lancet Neurology. 2020.Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J. Neurology(R) neuroimmunology & neuroinflammation. 2020.Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S; Tysabri Observational Program (TOP) Investigators. Journal of neurology, neurosurgery, and psychiatry. 2020.Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
Miller A.E.; Olsson T.P.; Wolinsky J.S.; Comi G.; Kappos L.; Hu X.; Xu X.; Lublin A.L.; Truffinet P.; Chavin J.; Delhay J.-L.; Benamor M.; Purvis A.; Freedman M.S.. Multiple sclerosis and related disorders. 2020.MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.
Sastre-Garriga J; Pareto D; Battaglini M; Rocca MA; Ciccarelli O; Enzinger C; Wuerfel J; Sormani MP; Barkhof F; Yousry TA; De Stefano N; Tintoré M; Filippi M; Gasperini C; Kappos L; Río J; Frederiksen J; Palace J; Vrenken H; Montalban X; Rovira À; MAGNIMS study group. Nature reviews. Neurology. 2020.Monitoring of radiologic disease activity by serum neurofilaments in MS.
Uher T; Schaedelin S; Srpova B; Barro C; Bergsland N; Dwyer M; Tyblova M; Vodehnalova K; Benkert P; Oechtering J; Leppert D; Naegelin Y; Krasensky J; Vaneckova M; Kubala Havrdova E; Kappos L; Zivadinov R; Horakova D; Kuhle J; Kalincik T. Neurology(R) neuroimmunology & neuroinflammation. 2020.Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease.
Kronlage C; Hardmeier M; Bally S; Scholz MC; Bucher HC; Müller OK; Winterhalder C; Mongiat M; Müller J; Polymeris A; Weber M; Lausberg C; Kassi E; Kuhle J; Kappos L; Hermann W; Bernsmeier C; Yaldizli Ö. The Lancet. 2020.Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Kuhle J; Plavina T; Barro C; Disanto G; Sangurdekar D; Singh CM; de Moor C; Engle B; Kieseier BC; Fisher E; Kappos L; Rudick RA; Goyal J. Multiple sclerosis (Houndmills, Basingstoke, England). 2020.New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö. Journal of Neurology. 2020.No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a
Freedman M.S.; Comi G.; Coyle P.K.; Aldridge J.; Chen L.; Marhardt K.; Kappos L.. Multiple sclerosis and related disorders. 2020.Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. The New England journal of medicine. 2020.Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I. Neurology. 2020.Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort.
de Sitter A; Verhoeven T; Burggraaff J; Liu Y; Simoes J; Ruggieri S; Palotai M; Brouwer I; Versteeg A; Wottschel V; Ropele S; Rocca MA; Gasperini C; Gallo A; Yiannakas MC; Rovira A; Enzinger C; Filippi M; De Stefano N; Kappos L; Frederiksen JL; Uitdehaag BMJ; Barkhof F; Guttmann CRG; Vrenken H; MAGNIMS Study Group. Journal of Neurology. 2020.Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.
Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Chen C; Parks B; Miller C. Therapeutic advances in neurological disorders. 2020.Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.
Steinheimer S; Dorn JF; Morrison C; Sarkar A; D'Souza M; Boisvert J; Bedi R; Burggraaff J; Kontschieder P; Dahlke F; Sellen A; Uitdehaag BMJ; Kappos L; Kamm CP. DISABILITY AND REHABILITATION. 2020.Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study
Magon S.; Pfister A.; Laura G.; Luthi M.; Papadopoulou A.; Kappos L.; Sprenger T.. Brain imaging and behavior. 2020.The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.
Derfuss T; Sastre-Garriga J; Montalban X; Rodegher M; Wuerfel J; Gaetano L; Tomic D; Azmon A; Wolf C; Kappos L. Multiple sclerosis journal - experimental, translational and clinical. 2020.Video-Based Pairwise Comparison: Enabling the Development of Automated Rating of Motor Dysfunction in Multiple Sclerosis.
Burggraaff J; Dorn J; D'Souza M; Morrison C; Kamm CP; Kontschieder P; Tewarie P; Steinheimer S; Sellen A; Dahlke F; Kappos L; Uitdehaag B. Archives of physical medicine and rehabilitation. 2020.Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT.
Cortese M; Munger KL; Martínez-Lapiscina EH; Barro C; Edan G; Freedman MS; Hartung HP; Montalbán X; Foley FW; Penner IK; Hemmer B; Fox EJ; Schippling S; Wicklein EM; Kappos L; Kuhle J; Ascherio A; BENEFIT Study Group. Neurology. 2020.Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T. Journal of Neurology. 2020.White matter lesion location correlates with disability in relapsing multiple sclerosis.
Gaetano L; Magnusson B; Kindalova P; Tomic D; Silva D; Altermatt A; Magon S; Müller-Lenke N; Radue EW; Leppert D; Kappos L; Wuerfel J; Häring DA; Sprenger T. Multiple sclerosis journal - experimental, translational and clinical. 2020.Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS.
Boligan KF; Oechtering J; Keller CW; Peschke B; Rieben R; Bovin N; Kappos L; Cummings RD; Kuhle J; von Gunten S; Lünemann JD. Neurology(R) neuroimmunology & neuroinflammation. 2020.A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases.
Sander L; Pezold S; Andermatt S; Amann M; Meier D; Wendebourg MJ; Sinnecker T; Radue EW; Naegelin Y; Granziera C; Kappos L; Wuerfel J; Cattin P; Schlaeger R; Alzheimer's Disease Neuroimaging Initiative. Human brain mapping. 2019.Alemtuzumab Reduces Serum Neurofilament Light Chain Levels in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: CARE-MS I
Kuhle, Jens; Daizadeh, Nadia; Barro, Christian; Michalak, Zuzanna; Leppert, David; Godin, Jean; Shankara, Srinivas; Samad, Tarek; Jacobs, Alan; Chung, Luke; Roesch, Nora; Kaiser, Carina; Havari, Evis; Kappos, Ludwig. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.
Zimmermann M; Rose N; Lindner JM; Kim H; Gonçalves AR; Callegari I; Syedbasha M; Kaufmann L; Egli A; Lindberg RLP; Kappos L; Traggiai E; Sanderson NSR; Derfuss T. Frontiers in Immunology. 2019.Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Lorscheider J; Kuhle J; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Hupperts R; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Sola P; Ferraro D; Trojano M; Ramo-Tello C; Lechner-Scott J; Pucci E; Solaro C; Slee M; Van Pesch V; Sanchez Menoyo JL; van der Walt A; Butzkueven H; Kappos L; Kalincik T; MSBase Study Group. European journal of neurology. 2019.Assessment of Cognitive Processing Speed in the Phase 3 Sunbeam Trial Demonstrates Sustained Improvement in Ozanimod-Treated Patients
DeLuca, John; Huang, Deren; Cohen, Jeffrey A.; Cree, Bruce A. C.; Chen, Yu; Campagnolo, Denise; Harvey, Danielle; Sheffield, James K.; Comi, Giancarlo; Kappos, Ludwig. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.
Cantó E; Barro C; Zhao C; Caillier SJ; Michalak Z; Bove R; Tomic D; Santaniello A; Häring DA; Hollenbach J; Henry RG; Cree BAC; Kappos L; Leppert D; Hauser SL; Benkert P; Oksenberg JR; Kuhle J. JAMA neurology. 2019.Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.
Pröbstel AK; Thanei M; Erni B; Lecourt AC; Branco L; André R; Roux-Lombard P; Koenig KF; Huynh-Do U; Ribi C; Chizzolini C; Kappos L; Trendelenburg M; Derfuss T; Swiss Systemic Lupus Erythematosus Cohort Study Group. Rheumatology (Oxford, England). 2019.Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T. JAMA neurology. 2019.Automatic Spinal Cord Gray Matter Quantification: A Novel Approach.
Tsagkas C; Horvath A; Altermatt A; Pezold S; Weigel M; Haas T; Amann M; Kappos L; Sprenger T; Bieri O; Cattin P; Parmar K. AJNR. American journal of neuroradiology. 2019.Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.
Sormani MP; Haering DA; Kropshofer H; Leppert D; Kundu U; Barro C; Kappos L; Tomic D; Kuhle J. Annals of Clinical and Translational Neurology. 2019.Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L. Neurology. 2019.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL. Brain : a journal of neurology. 2019.Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study.
Altermatt A; Gaetano L; Magon S; Bauer L; Feurer R; Gnahn H; Hartmann J; Seifert CL; Poppert H; Wuerfel J; Radue EW; Kappos L; Sprenger T. NeuroImage. 2019.Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H. Journal of neurology, neurosurgery, and psychiatry. 2019.Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway.
Papadopoulou A; Gaetano L; Pfister A; Altermatt A; Tsagkas C; Morency F; Brandt AU; Hardmeier M; Chakravarty MM; Descoteaux M; Kappos L; Sprenger T; Magon S. Neurology. 2019.Design and construction of an innovative brain phantom prototype for MRI.
Altermatt A; Santini F; Deligianni X; Magon S; Sprenger T; Kappos L; Cattin P; Wuerfel J; Gaetano L. Magnetic Resonance in Medicine. 2019.Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
Bridel C; van Wieringen WN; Zetterberg H; Tijms BM; Teunissen CE; and the NFL Group; Alvarez-Cermeño JC; Andreasson U; Axelsson M; Bäckström DC; Bartos A; Bjerke M; Blennow K; Boxer A; Brundin L; Burman J; Christensen T; Fialová L; Forsgren L; Frederiksen JL; Gisslén M; Gray E; Gunnarsson M; Hall S; Hansson O; Herbert MK; Jakobsson J; Jessen-Krut J; Janelidze S; Johannsson G; Jonsson M; Kappos L; Khademi M; Khalil M; Kuhle J; Landén M; Leinonen V; Logroscino G; Lu CH; Lycke J; Magdalinou NK; Malaspina A; Mattsson N; Meeter LH; Mehta SR; Modvig S; Olsson T; Paterson RW; Pérez-Santiago J; Piehl F; Pijnenburg YAL; Pyykkö OT; Ragnarsson O; Rojas JC; Romme Christensen J; Sandberg L; Scherling CS; Schott JM; Sellebjerg FT; Simone IL; Skillbäck T; Stilund M; Sundström P; Svenningsson A; Tortelli R; Tortorella C; Trentini A; Troiano M; Turner MR; van Swieten JC; Vågberg M; Verbeek MM; Villar LM; Visser PJ; Wallin A; Weiss A; Wikkelsø C; Wild EJ. JAMA neurology. 2019.Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ. Neurology. 2019.Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Buck D; Andlauer TF; Igl W; Wicklein EM; Mühlau M; Weber F; Köchert K; Pohl C; Arnason B; Comi G; Cook S; Filippi M; Hartung HP; Jeffery D; Kappos L; Barkhof F; Edan G; Freedman MS; Montalbán X; Müller-Myhsok B; Hemmer B; BEYOND and BENEFIT Study Groups. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L; RADIANCE Trial Investigators. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Evaluation of Long-Term Treatment of Teriflunomide on Cognitive Outcomes and Association with Brain Volume Change: Data From the TEMSO Study and its Extension
Lechner-Scott, J.; Sprenger, T.; Sormani, M. P.; Wuerfel, J.; Thangavelu, K.; Cavalier, S.; Mandel, M.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
Sinnecker T; Clarke MA; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Kappos L; Montalban X; Rovira À; Evangelou N; Wuerfel J; MAGNIMS Study Group. JAMA neurology. 2019.Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
Cohen J.A.; Tenenbaum N.; Bhatt A.; Zhang Y.; Kappos L.. Therapeutic advances in neurological disorders. 2019.Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.
Diebold M; Fischer-Barnicol B; Tsagkas C; Kuhle J; Kappos L; Derfuss T; Décard BF. Neurology(R) neuroimmunology & neuroinflammation. 2019.Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases
Motte J.; Kneiphof J.; Strassburger-Krogias K.; Pitarokoili K.; Fisse A.L.; Kappos L.; Gold R.. Therapeutic advances in neurological disorders. 2019.Learning ability correlates with brain atrophy and disability progression in RRMS.
Sormani MP; De Stefano N; Giovannoni G; Langdon D; Piani-Meier D; Haering DA; Kappos L; Tomic D. Journal of neurology, neurosurgery, and psychiatry. 2019.Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis from the BOLD and EXPAND Trial and their Extensions
Kappos, L.; Vermersche, P.; Fox, R.; Bar-Or, A.; Cree, B.; Giovannoni, G.; Gold, R.; Masior, T.; Meier, Piani P.; Tomic, D.; Rouyrre, N.; Dahlke, F.; Karlsson, G.; Bakshi, R.; Kilaru, A.; Selmaj, K.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Long-Term Clinical Outcomes in Patients with CIS Treated with Interferon Beta-1b: First Results from Benefit 15
Freedman, Mark S.; Kappos, Ludwig; Edan, Gilles; Hartung, Hans-Peter; Montalban, Xavier; Barkhof, Frederik; Wicklein, Eva-Maria. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★
Miller A.E.; Vermersch P.; Kappos L.; Comi G.; Freedman M.S.; Oh J.; de Seze J.; Truffinet P.; Benamor M.; Purvis A.; Wolinsky J.S.. Multiple sclerosis and related disorders. 2019.MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.
Bendfeldt K; Taschler B; Gaetano L; Madoerin P; Kuster P; Mueller-Lenke N; Amann M; Vrenken H; Wottschel V; Barkhof F; Borgwardt S; Klöppel S; Wicklein EM; Kappos L; Edan G; Freedman MS; Montalbán X; Hartung HP; Pohl C; Sandbrink R; Sprenger T; Radue EW; Wuerfel J; Nichols TE. Brain imaging and behavior. 2019.Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS
Lavie, Caroline; Rollot, Fabien; Durand-Dubief, Francoise; Marignier, Romain; Ionescu, Iuliana; Casey, Romain; Moreau, Thibault; Tourniaire, Patricia; Hutchinson, Michael; D'Hooghe, Marie Beatrice; Laplaud, David-Axel; Clavelou, Pierre; De Seze, Jerome; Debouverie, Marc; Brassat, David; Pelletier, Jean; Lebrun-Frenay, Christine; Le Page, Emmanuelle; Castelnovo, Giovanni; Berger, Eric; Hautecoeur, Patrick; Heinzlef, Olivier; Durelli, Luca; Clerico, Marinella; Trojano, Maria; Patti, Francesco; Vukusic, Sandra; Alperovitch, A.; Carton, H.; d'Hooghe, M. B.; Hommes, O.; Hutchinson, M.; Adeleine, P.; Biron, A.; Cortinovis-Tourniaire, P.; Grimaud, J.; Hours, M.; Moreau, T.; Vukusic, S.; Confavreux, C.; Chauplannaz, G.; Confavreux, C.; Cortinovis-Tourniaire, P.; Grimaud, J.; Latombe, D.; Moreau, T.; Clanet, M.; Lau, G.; Rumbach, L.; Goas, J. Y.; Rouhart, F.; Mazingue, A.; Roullet, E.; Madigand, M.; Hautecoeur, P.; Brunet, P.; Edan, G.; Allaire, C.; Leche, J.; Benoit, T.; Simonin, C.; Ziegler, F.; Baron, J. C.; Rivrain, Y.; Dumas, R.; Loche, D.; Bourrin, J. C.; Huttin, B.; Delisse, B.; Gibert, I.; Boulay, C.; Verceletto, M.; Durand, G.; Bonneviot, G.; Gil, R.; Hedreville, M. A.; Belair, C.; Poitevin, R. J.; Devoize, J. L.; Wyremblewski, P.; Delestre, F.; Setiey, A.; Comi, G.; Filippi, M.; Ghezzi, A.; Martinelli, V.; Rossi, P.; Zaffaroni, M.; Tola, M. R.; Amato, M. P.; Fioretti, C.; Meucci, G.; Inglese, M.; Mancardi, G. L.; Gambi, D.; Thomas, A.; Cavazzuti, M.; Citterio, A.; Heltberg, A.; Hansen, H. J.; Fernandez, O.; Romero, F.; Arbizu, T.; Hernandez, J. J.; De Andres de Frutos, C.; Geffner Sclarky, D.; Aladro Benito, Y.; Reyes Yanes, P.; Aguilar, M.; Burguera, J. A.; Yaya, R.; Bonakim Dib, W.; Arzua-Mouronte, D.; d'Hooghe, M. B.; Sindic, C. J. M.; Carton, H.; Medaer, R.; Roose, H.; Geens, K. M. J.; Guillaume, D.; Van Zandycke, M.; Janssens, J.; Cornette, M.; Mol, L.; Weilbach, F.; Flachenecker, P.; Hartung, H. P.; Haas, J.; Tendolkar, I.; Sindrn, E.; Kolmel, H. W.; Reichel, D.; Rauch, M.; Preuss, S.; Poser, S.; Mauch, E.; Strausser-Fuchs, S.; Kolleger, H.; Hawkins, S.; Howell, S. J. L.; Rees, J. E.; Thompson, A.; Johnson, M.; Boggild, M.; Gregory, R. P.; Bates, D.; Bone, I.; Hutchinson, M.; Polman, C.; Frequin, S.; Jongen, P.; Hommes, O.; Correia de Sa, J.; Rio, M. E.; Huber, S.; Lechner-Scott, J.; Kappos, L.; Ionescu, I.; Cornu, C.; Confavreux, C.; Vukusic, S.; El-Etr, M.; Baulieu, E. E.; El-Etr, M.; Schumacher, M.; Ionescu, I.; Confavreux, C.; Cornu, C.; Vukusic, S.; Hartung, H. P.; Miller, D. H.; Hutchinson, M.; Pugeat, M.; d'Archangues, C.; Conard, J.; Menard, J.; Sitruk-Ware, R.; Pelissier, C.; Dat, S.; Belaisch-Allard, J.; Athea, N.; Buschsenschutz, D.; Lyon-Caen, O.; Gonsette, R.; Boissel, J. P.; Ffrench, P.; Durand-Dubief, F.; Cotton, F.; Pachai, C.; Bracoud, L.; Vukusic, S.; Ionescu, I.; Androdias, G.; Marignier, R.; Chauplannaz, G.; Laplaud, D. A.; Wiertlewski, S.; Lanctin-Garcia, C.; Moreau, T.; Couvreur, G.; Madinier, G.; Clavelou, P.; Taithe, F.; Aufauvre, D.; Guy, N.; Ferrier, A.; De Seze, J.; Collongues, N.; Debouverie, M.; Viala, F.; Brassat, D.; Gerdelat-Mas, A.; Henry, P.; Pelletier, J.; Rico-Lamy, A.; Lebrun-Frenay, C.; Lepage, E.; Deburghraeve, V.; Edan, G.; Castelnovo, G.; Berger, E.; Hautecoeur, P.; Blondiau, M.; Heinzlef, O.; Coustans, M.; Clerc, C.; Rieu, L.; Lauxerois, M.; Hinzelin, G.; Ouallet, J. C.; Minier, D.; Vion, P.; Gromaire-Fayolle, N.; Derache, N.; Thouvenot, E.; Sallansonnet-Froment, M.; Tourniaire, P.; Toureille, L.; Borgel, F.; Stankoff, B.; Grimaud, J.; Moroianu, C.; Guennoc, A. M.; Tournier-Gervason, C. L.; Peysson, S.; Trojano, M.; Patti, F.; D'Amico, E.; Motti, L.; Zaffaroni, M.; Durelli, L.; Tavella, A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Neurofilament Light Chain Serum Levels Correlate with 10-Year MRI Outcomes in Multiple Sclerosis
Chitnis, Tanuja; Gonzalez, Cindy T.; Healy, Brian C.; Saxena, Shrishti; Rosso, Mattia; Barro, Christian; Michalak, Zuzanna; Paul, Anu; Kivisakk, Pia; Diaz-Cruz, Camilo; Sattarnezhad, Neda; Pierre, Isabelle; Glanz, Bonnie I.; Tomic, Davorka; Kropshofer, Harald; Haring, Dieter A.; Leppert, David; Kappos, Ludwig; Bakshi, Rohit; Weiner, Howard L.; Kuhle, Jens. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Neurofilament Light Levels in the Blood of Patients with Secondary Progressive MS are Higher Than in Primary Progressive MS and may Predict Brain Atrophy in Both MS Subtypes
Leppert, D.; Kuhle, J.; Kropshofer, H.; Haring, D. A.; Barro, C.; Dahlke, F.; Tomic, D.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B; Cree BAC; Kappos L; Montalban X; Papeix C; Wolinsky JS; Buffels R; Fiore D; Garren H; Han J; Hauser SL. Journal of Neurology. 2019.Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies
Mayer L.; Kappos L.; Racke M.K.; Rammohan K.; Traboulsee A.; Hauser S.L.; Julian L.; Kondgen H.; Li C.; Napieralski J.; Zheng H.; Wolinsky J.S.. Multiple sclerosis and related disorders. 2019.Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Barkhof F.; Kappos L.; Wolinsky J.S.; Li D.K.B.; Bar-Or A.; Hartung H.-P.; Belachew S.; Han J.; Julian L.; Sauter A.; Napieralski J.; Koendgen H.; Hauser S.L.. Neurology. 2019.PARP-1 deregulation in multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Bodmer H; Derfuss T; Kuhle J; Haghikia A; Kappos L; Lindberg RL. Multiple sclerosis journal - experimental, translational and clinical. 2019.PML with dimethyl fumarate-No convincing case against natalizumab.
Diebold M; Altersberger V; Décard BF; Kappos L; Derfuss T; Lorscheider J. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients with Relapsing-Remitting Multiple Sclerosis
Kappos, L.; Meier, D. P.; Tomic, T.; Haring, D.; Bakshi, R.; Meinert, R.; Giovannoni, G.; Chitnis, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L; RADIANCE Trial Investigators. The Lancet Neurology. 2019.Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Comi G.; Kappos L.; Selmaj K.W.; Bar-Or A.; Arnold D.L.; Steinman L.; Hartung H.-P.; Montalban X.; Kubala Havrdova E.; Cree B.A.C.; Sheffield J.K.; Minton N.; Raghupathi K.; Ding N.; Cohen J.A.. The Lancet Neurology. 2019.Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Serum Neurofilament Light Chain Levels Correlate with Disease Characteristics in Patients with Relapsing-Remitting Multiple Sclerosis from CARE-MS I
Kuhle, Jens; Daizadeh, Nadia; Barro, Christian; Michalak, Zuzanna; Leppert, David; Godin, Jean; Shankara, Srinivas; Samad, Tarek; Jacobs, Alan; Chung, Luke; Roesch, Nora; Kaiser, Carina; Havari, Evis; Kappos, Ludwig. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Siponimod Improves Cognitive Processing Speed in Patients with Secondary Progressive Multiple Sclerosis: EXPAND Subgroup Analyses
Benedict, R.; Tomic, D.; Fox, R.; Cree, B.; Vermersch, P.; Giovannoni, G.; Bar-Or, A.; Gold, R.; Ritter, Sh.; Karlsson, G.; Wolf, C.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.
Ciccarelli O; Cohen JA; Reingold SC; Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.. The Lancet Neurology. 2019.Sustained Improvement in Cognitive Processing Speed in Multiple Sclerosis Patients Completing 18 Months of Ozanimod Treatment: Results From the Phase 3 SUNBEAM Trial
DeLuca, J.; Cohen, J. A.; Cree, B. A. C.; Chen, Y.; Harvey, D.; Sheffield, J. K.; Silva, D.; Comi, G.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
van Munster CE; D'Souza M; Steinheimer S; Kamm CP; Burggraaff J; Diederich M; Kravalis K; Dorn J; Walsh L; Dahlke F; Kappos L; Uitdehaag BM. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
Gasperini C; Prosperini L; Tintoré M; Sormani MP; Filippi M; Rio J; Palace J; Rocca MA; Ciccarelli O; Barkhof F; Sastre-Garriga J; Vrenken H; Frederiksen JL; Yousry TA; Enzinger C; Rovira A; Kappos L; Pozzilli C; Montalban X; De Stefano N; the MAGNIMS Study Group. Neurology. 2019.Volume Loss in Deep Gray Matter and Thalamic Sub-Nuclei in Placebo-Treated Patients with Multiple Sclerosis in the Phase 3 Temso Study
Gaetano, Laura; Magon, Stefano; Chakravarty, Mallar; Kappos, Ludwig; Sprenger, Till; Cavalier, Steven J.; Roesch, Nora; Thangavelu, Karthinathan; Wuerfel, Jens. Multiple sclerosis (Houndmills, Basingstoke, England). 2019.A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.
Nakamura Y; Gaetano L; Matsushita T; Anna A; Sprenger T; Radue EW; Wuerfel J; Bauer L; Amann M; Shinoda K; Isobe N; Yamasaki R; Saida T; Kappos L; Kira JI. Journal of neuroinflammation. 2018.Alemtuzumab reduces serum neurofilament light chain levels in relapsing-remitting multiple sclerosis patients from the CARE-MS I study
Kuhle, J.; Daizadeh, N.; Barro, C.; Michalak, Z.; Godin, J.; Shankara, S.; Samad, T. A.; Jacobs, A.; Chung, L.; Roesch, N.; Kaiser, C.; Havari, E.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.A Long-term Experience with Fingolimod: Evaluation of Safety, Disability, and Treatment Satisfaction in Patients with Relapsing-Remitting Multiple Sclerosis
Tenenbaum, Nadia; Cohen, Jeffrey; Bhatt, Alit; Pimentel, Ron; Kappos, Ludwig. Neurology. 2018.An integral measure of serial neurofilament light chain assessments in blood is a predictor of long-term disability progression in relapsing-remitting multiple sclerosis
Kuhle, J.; Cohen, J.; Haring, D. A.; Kropshofer, H.; Leppert, D.; Tomic, D.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
Hauser, Stephen; Brochet, Bruno; Montalban, Xavier; Naismith, Robert; Wolinsky, Jerry; Manfrini, Marianna; Garas, Monika; Villoslada, Pablo; Model, Fabian; Hubeaux, Stanislas; Kappos, Ludwig. Neurology. 2018.Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.
Miller DH; Lublin FD; Sormani MP; Kappos L; Yaldizli Ö; Freedman MS; Cree BAC; Weiner HL; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; MacManus DG; Yousry TA; Gandini Wheeler-Kingshott CAM; Li B; Putzki N; Merschhemke M; Häring DA; Wolinsky JS. Annals of Clinical and Translational Neurology. 2018.Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis
Arnold, Douglas; Kappos, Ludwig; Hauser, Stephen; Montalban, Xavier; Traboulsee, Anthony; Wolinsky, Jerry; Levesque, Victoria; Villoslada, Pablo; Belachew, Shibeshih; Model, Fabian; Hubeaux, Stanislas; Bar-Or, Amit. Neurology. 2018.Brainstem atrophy in multiple sclerosis correlates with disability
Sander, L.; Pezold, S.; Andermatt, S.; Amann, M.; Wendebourg, M. J.; Sinnecker, T.; Naegelin, Y.; Granziera, C.; Kappos, L.; Wuerfel, J.; Cattin, P.; Schlaeger, R.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.
Ruberte E; Sinnecker T; Amann M; Gaetano L; Naegelin Y; Penner IK; Kuhle J; Derfuss T; Kappos L; Granziera C; Wuerfel J; Yaldizli Ö. European Neurology. 2018.Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon beta-1a in Relapsing Multiple Sclerosis (RMS)
Cohen, Jeffrey; Comi, Giancarlo; Selmaj, Krzysztof; Bar-Or, Amit; Arnold, Douglas; Steinman, Lawrence; Hartung, Hans-Peter; Montalban, Xavier; Havrdova, Eva; Cree, Bruce; Sheffield, James; Raghupathi, Kartik; Kappos, Ludwig. Neurology. 2018.Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.
Altermatt A; Gaetano L; Magon S; Häring DA; Tomic D; Wuerfel J; Radue EW; Kappos L; Sprenger T. BRAIN TOPOGRAPHY. 2018.Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971].
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L. CLINICAL THERAPEUTICS. 2018.Defining extracellular RNA (exRNA) expression as an indicator for natalizumab treatment response and PML risk assessment in multiple sclerosis
Meira, M.; Lagarde, N.; Ritz, S.; Derfuss, T.; Kuhle, J.; Kappos, L.; Lindberg, R.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Detecting response to fampridine on motor functioning with activities of daily living and classical neurological examinations in multiple sclerosis patients
Lam, K. -H.; van Munster, C. E. P.; D'Souza, M.; Steinheimer, S.; Kamm, C. P.; Burggraaff, J.; Boisvert, J.; Diederich, M.; Kravalis, K.; Dorn, J.; Walsh, L.; Dahlke, F.; Kappos, L.; Killestein, J.; Uitdehaag, B. M. J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ; Banwell BL; Barkhof F; Carroll WM; Coetzee T; Comi G; Correale J; Fazekas F; Filippi M; Freedman MS; Fujihara K; Galetta SL; Hartung HP; Kappos L; Lublin FD; Marrie RA; Miller AE; Miller DH; Montalban X; Mowry EM; Sorensen PS; Tintoré M; Traboulsee AL; Trojano M; Uitdehaag BMJ; Vukusic S; Waubant E; Weinshenker BG; Reingold SC; Cohen JA. The Lancet Neurology. 2018.Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
Diebold M.; Sievers C.; Bantug G.; Sanderson N.; Kappos L.; Kuhle J.; Lindberg R.L.P.; Derfuss T.. Journal of autoimmunity. 2018.ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F. European journal of neurology. 2018.ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Efficacy and safety of continuous fingolimod treatment for at least 5 years in patients with relapsing-remitting multiple sclerosis: analysis of LONGTERMS data
Kappos, L.; Tenenbaum, N.; Bhatt, A.; Couturier, A.; Cohen, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
Cohan S; Kappos L; Giovannoni G; Wiendl H; Selmaj K; Havrdová EK; Rose J; Greenberg S; Phillips G; Ma W; Wang P; Lima G; Sabatella G. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Efficacy of Ozanimod Versus Interferon beta-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B)
Kappos, Ludwig; Selmaj, Krzysztof; Bar-Or, Amit; Comi, Giancarlo; Arnold, Douglas; Steinman, Lawrence; Hartung, Hans-Peter; Montalban, Xavier; Havrdova, Eva; Sheffield, James; Raghupathi, Kartik; Cree, Bruce; Cohen, Jeffrey. Neurology. 2018.Electronic Neurostatus-EDSS increases quality of expanded disability status scale (EDSS) assessments: first experience from two phase 3 clinical trials with ofatumumab in relapsing multiple sclerosis using the Web Diary
D'Souza, M.; Gysin, S.; Heikkila, A.; Lorscheider, J.; Haller, V.; Kravalis, K.; Norman, N.; Higgins, P.; Lam, E.; Kakarieka, A.; Tomic, D.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L. Annals of neurology. 2018.Evaluation of Teriflunomide in Children and Adolescents With Relapsing MS: TERIKIDS Phase 3 Study Design, Enrollment Update, and Baseline Data
Chitnis, Tanuja; Tardieu, Marc; Banwell, Brenda; Gucuyener, Kivilcim; Deiva, Kumaran; Skripchenko, Natalia; Anlar, Banu; Robinson, Miqun; Deng, Rita; Dupin, Margaux; Truffinet, Philippe; Jurgensen, Stephanie; Chavin, Jeffrey; Kappos, Ludwig. Neurology. 2018.Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T. Neurology. 2018.Four-week in-patient multidisciplinary rehabilitation program in multiple sclerosis: behavioural and fMRI results
Zuber, P.; Tsagkas, C.; Papadopoulou, A.; Huerbin, M.; Gaetano, L.; Geiter, E.; Altermatt, A.; Parmar, K.; Ettlin, T.; Schuster-Amft, C.; Suica, Z.; Alrasheed, H.; Wuerfel, J.; Kesselring, J.; Kappos, L.; Sprenger, T.; Magon, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Ganglion cell layer volume and serum neurofilaments are associated with disability in multiple sclerosis
Mickeliunas, G.; Michalak, Z.; Barro, C.; Stoessel, M.; Calabrese, P.; Derfuss, T.; Naegelin, Y.; Kuhle, J.; Kappos, L.; Papadopoulou, A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M; Tysabri® Observational Program (TOP) Investigators. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Growth-differentiation factor 15 (GDF-15) is increased in serum of stable multiple sclerosis patients
Amstad, A.; Frick, C.; Barro, C.; Recher, M.; Berger, C.; Wischhusen, J.; Kappos, L.; Naegelin, Y.; Kuhle, J.; Mehling, M.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Hepatitis E virus infections as a possible complication of immunomodulatory treatment in multiple sclerosis
Diebold, M.; Fischer-Barnicol, B.; Tsagkas, C.; Kuhle, J.; Kappos, L.; Derfuss, T.; Decard, B. F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease
Benedict, Ralph; De Seze, Jerome; Hauser, Stephen; Kappos, Ludwig; Wolinsky, Jerry; Zheng, Hanzhe; Belachew, Shibeshih; Julian, Laura; Villoslada, Pablo; Lublin, Fred. Neurology. 2018.Impact of ozanimod on early and advanced relapsing multiple sclerosis: annualised relapse rate and MRI endpoints from two randomised, multicentre, doubleblind, Phase 3 studies (SUNBEAM and RADIANCE)
Comi, G.; Kappos, L.; Cree, B. A. C.; Arnold, D. L.; Selmaj, K. W.; Bar-Orb, A.; Steinman, L.; Hartung, H. -P.; Montalban, X.; Havrdova, E. K.; Ferguson, B.; Sheffield, J. K.; Cohen, J. A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study
Benedict, Ralph H. B.; Cree, Bruce; Tomic, Davorka; Fox, Robert; Giovannoni, Gavin; Bar-Or, Amit; Gold, Ralf; Vermersch, Patrick; Pohlmann, Harald; Karlsson, Goril; Dahlke, Frank; Kappos, Ludwig. Neurology. 2018.Impact of the Presence of Gadolinium-Enhancing (Gd plus ) Lesions at Baseline on No Evidence of Disease Activity (NEDA) Status in Patients Treated with Subcutaneous Interferon beta-1a (scIFN beta-1a): A Post-hoc Analysis of REFLEXION
Freedman, Mark S.; Comi, Giancarlo; Coyle, Patricia K.; Aldridge, Julie; Marhardt, Kurt; Kappos, Ludwig. Neurology. 2018.Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time
Giovannoni, G.; Kappos, L.; Berger, J.; Cutter, G.; Fox, R. J.; Wiendl, H.; Chang, I.; Kasliwal, R.; Lee, L.; Licata, S.; Ho, P. -R.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing-Remitting Multiple Sclerosis Trials
Sormani, Maria Pia; Kappos, Ludwig; Haring, Dieter; Kropshofer, Harald; Barro, Christian; Leppert, David; Tomic, Davorka; Kuhle, Jens. Neurology. 2018.International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients
Kuhle, J.; Barro, C.; Hrusovsky, K.; Chang, L.; Jeromin, A.; Bridel, C.; Bar-Or, A.; Bittner, S.; Brueck, W.; Bielekova, B.; Chitnis, T.; Comi, G.; Comabella, M.; Arrambide, G.; Montalban, X.; Datwani, A.; Fluck, M.; Fox, R.; Freedman, M.; Furlan, R.; Gnanapavan, S.; Giovannoni, G.; Havari, E.; Khalil, M.; Leppert, D.; Kropshofer, H.; Valentin, M. A.; Oksenberg, J.; Piehl, F.; Plavina, T.; Sormani, M. P.; Lehmann, S.; Thouvenot, E.; Ziemssen, T.; Zipp, F.; Gross, C.; Wiendl, H.; Kappos, L.; Michalak, Z.; Blennow, K.; Zetterberg, H.; Teunissen, C.; Wilson, D.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Longer duration of natalizumab exposure may lessen return of disease activity following a switch from natalizumab to an oral therapy: modelling real-world data from relapsing-remitting multiple sclerosis (RRMS) patients in the TYSABRI (R) Observational Program (TOP)
Butzkueven, Helmut; Wiendl, Heinz; Trojano, Maria; Kappos, Ludwig; Spelman, Timothy; Rosales, Karen; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan. Neurology. 2018.Long-Term Disease Control with Fingolimod in RRMS Patients With Active Disease
Havrdova, Eva Kubala; Silva, Diego; Kappos, Ludwig; Meinert, Rolf; Cohen, Jeffrey; Devonshire, Virginia. Neurology. 2018.Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients
Kuhle, Jens; Cohen, Jeffery A.; Kropshofer, Harald; Meinert, Rolf; Barro, Christian; Merschhemke, Martin; Haring, Dieter; Leppert, David; Tomic, Davorka; Kappos, Ludwig. Neurology. 2018.Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
Arnold, D. L.; Kappos, L.; Hauser, S. L.; Montalban, X.; Traboulsee, A.; Wolinsky, J. S.; Manfrini, M.; Levesque, V.; Villoslada, P.; Belachew, S.; Model, F.; Hubeaux, S.; Bar-Or, A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
Hauser, S. L.; Brochet, B.; Montalban, X.; Naismith, R. T.; Wolinsky, J. S.; Manfrini, M.; Garas, M.; Villoslada, P.; Model, F.; Hubeaux, S.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum.
Naegelin Y; Dingsdale H; Säuberli K; Schädelin S; Kappos L; Barde YA. eNeuro. 2018.Measuring plasma glial fibrillary acidic protein in multiple sclerosis - an easily accessible marker of astrogliosis?
Barro, C.; Benkert, P.; Groebke, S.; Michalak, Z.; Kappos, L.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.MRI brain T1 gray matter/white matter contrast in multiple sclerosis versus migraine using magnetization prepared rapid gradient echo (MPRAGE) sequences.
Mitrovic, T.; Sinnecker, T.; Amann, M.; Calabrese, P.; Naegelin, Y.; Derfuss, T.; Decard, B.; Kuhle, J.; Gaetano, L.; Wuerfel, J.; Kappos, L.; Granziera, C.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Natalizumab is associated with a reduction in relapse-related hospitalisations and steroid treatment in relapsing-remitting multiple sclerosis patients enrolled in the TYSABRI (R) Observational Program
Trojano, M.; Spelman, T.; Butzkueven, H.; Kappos, L.; Wiendl, H.; Chang, I.; Naoshy, S.; Ho, P. -R.; Licata, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
Trojano M.; Butzkueven H.; Kappos L.; Wiendl H.; Spelman T.; Pellegrini F.; Chen Y.; Dong Q.; Koendgen H.; Belachew S.. Multiple sclerosis and related disorders. 2018.Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.
Chitnis T; Gonzalez C; Healy BC; Saxena S; Rosso M; Barro C; Michalak Z; Paul A; Kivisakk P; Diaz-Cruz C; Sattarnezhad N; Pierre IV; Glanz BI; Tomic D; Kropshofer H; Häring D; Leppert D; Kappos L; Bakshi R; Weiner HL; Kuhle J. Annals of Clinical and Translational Neurology. 2018.Neurofilaments as biomarkers in neurological disorders.
Khalil M; Teunissen CE; Otto M; Piehl F; Sormani MP; Gattringer T; Barro C; Kappos L; Comabella M; Fazekas F; Petzold A; Blennow K; Zetterberg H; Kuhle J. Nature reviews. Neurology. 2018.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Havrdová E; Arnold DL; Bar-Or A; Comi G; Hartung HP; Kappos L; Lublin F; Selmaj K; Traboulsee A; Belachew S; Bennett I; Buffels R; Garren H; Han J; Julian L; Napieralski J; Hauser SL; Giovannoni G. Multiple sclerosis journal - experimental, translational and clinical. 2018.Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis
Elliott, Colm; Wolinsky, Jerry; Hauser, Stephen; Kappos, Ludwig; Barkhof, Frederik; Model, Fabian; Wei, Wei; Bernasconi, Corrado; Belachew, Shibeshih; Arnold, Douglas. Neurology. 2018.Ofatumumab versus teriflunomide in relapsing multiple sclerosis: baseline characteristics of two pivotal phase 3 trials (ASCLEPIOS I and ASCLEPIOS II)
Kappos, L.; Bar-Or, A.; Cohen, J.; Comi, G.; Correale, J.; Coyle, P. K.; Cross, A. H.; De Seze, J.; Montalban, X.; Selmaj, K.; Wiendl, H.; Kerloeguen, C.; Willi, R.; Haering, D. A.; Leppert, D.; Goodyear, A.; Tomic, D.; Kakarieka, A.; Hauser, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Oral drugs versus interferon-beta or glatiramer acetate as first-line disease modifying therapy in relapsing-remitting multiple sclerosis
Benkert, P.; Lienert, C.; Lorscheider, J.; Hanni, P.; Decard, B.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Overall Response Score: A Novel Disability Endpoint That Allows for the Integrated Assessment of Improvement and Worsening over Time in Patients with MS
Chang, Ih; Kappos, Ludwig; Giovannoni, Gavin; Calabresi, Peter A.; Sandrock, Alfred; Chai, Yi; Zhu, Bing; Castrillo-Viguera, Carmen; Deykin, Aaron; Sheikh, Sarah. Neurology. 2018.Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM)
Comi, Giancarlo; Arnold, Douglas; Cree, Bruce; Kappos, Ludwig; Selmaj, Krzysztof; Bar-Or, Amit; Steinman, Lawrence; Hartung, Hans-Peter; Montalban, Xavier; Havrdova, Eva; Sheffield, James; Raghupathi, Kartik; Cohen, Jeffrey. Neurology. 2018.Ozanimod reduces rates of annualised relapse requiring steroids or hospitalisation versus interferon beta-1a: pooled results from two multicentre, randomised, double-blind, phase 3 studies in relapsing multiple sclerosis (SUNBEAM and RADIANCE)
Comi, G.; Kappos, L.; Hartung, H-P.; Cree, B. A. C.; Selmaj, K. W.; Bar-Or, A.; Steinman, L.; Arnold, D. L.; Montalban, X.; Havrdova, E. K.; Sheffield, J. K.; Campagnolo, D.; Ferguson, B.; Cohen, J. A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Ozanimod-treated patients exhibited improvements in cognitive processing speed in the phase 3 SUNBEAM trial of relapsing multiple sclerosis (RMS)
Deluca, J.; Huang, D.; Cohen, J. A.; Cree, B. A. C.; Chen, Y.; Campagnolo, D.; Sheffield, J. K.; Comi, G.; Kappos, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Plasma neurofilament light levels are associated with risk of developing sustained disability in multiple sclerosis
Manouchehrinia, A.; Delcoigne, B.; Barro, C.; Michalak, Z.; Alfredsson, L.; Kappos, L.; Piehl, F.; Olsson, T.; Kuhle, J.; Kockum, I.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Plasma neurofilament light levels segregate treatment effects: results from the IMSE studies with multiple disease modulatory drugs.
Delcoigne, B.; Manouchehrinia, A.; Barro, C.; Michalak, Z.; Kappos, L.; Leppert, D.; Tsai, J.; Plavina, T.; Kieseier, B. C.; Alfredsson, L.; Kockum, I.; Kuhle, J.; Olsson, T.; Piehl, F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H. Journal of the neurological sciences. 2018.Pregnancy outcomes in patients with multiple sclerosis and other autoimmune diseases treated with ocrelizumab in clinical trials and post-marketing studies
Vukusic, S.; Kappos, L.; Wray, S.; Bader-Weder, S.; Buffels, R.; Masterman, D.; Napieralski, J.; Hauser, S. L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Radiological findings suggest long-term treatment with delayed-release dimethyl fumarate is associated with tissue and axonal preservation
Arnold, D. L.; Kappos, L.; Gold, R.; Chen, C.; Yang, L.; Miller, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
De Stefano N; Giorgio A; Tintoré M; Pia Amato M; Kappos L; Palace J; Yousry T; Rocca MA; Ciccarelli O; Enzinger C; Frederiksen J; Filippi M; Vrenken H; Rovira À; MAGNIMS study group. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Rapid and reliable, fully-automated brainstem segmentation for application in multiple sclerosis
Sander, L.; Andermatt, S.; Pezold, S.; Amann, M.; Meier, D.; Sinnecker, T.; Wendebourg, M. J.; Naegelin, Y.; Granziera, C.; Kappos, L.; Wuerfel, J.; Cattin, P.; Schlaeger, R.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Real-world data from over 10 years in the TYSABRI (R) Observational Program: long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients
Kappos, L.; Butzkueven, H.; Spelman, T.; Trojano, M.; Wiendl, H.; Jiang, X.; Kasliwal, R.; Campbell, N.; Ho, P. -R.; Licata, S.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Real-world improvement across functional systems (FS) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab in the TYSABRI (R) Observational Program (TOP)
Wiendl, Heinz; Butzkueven, Helmut; Kappos, Ludwig; Spelman, Timothy; Trojano, Maria; Rosales, Karen; Campbell, Nolan; Ho, Pei-Ran; Licata, Stephanie. Neurology. 2018.Recurrence of disease activity after fingolimod discontinuation - observations in a real-world cohort with 433 multiple sclerosis patients.
Cerda, N.; Nagy, S.; Sinnecker, T.; Wurfel, J.; Kuhle, J.; Yaldizli, O.; Kappos, L.; Derfuss, T.; Decard, B. F.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.
D'Souza M; Steinheimer S; Dorn J; Morrison C; Boisvert J; Kravalis K; Burggraaff J; van Munster CE; Diederich M; Sellen A; Kamm CP; Dahlke F; Uitdehaag BM; Kappos L. Multiple sclerosis journal - experimental, translational and clinical. 2018.Relationship between overall response score of disability in MS with patient-reported outcome SF-36
Chang, I.; Giovannoni, G.; Kappos, L.; Calabresi, P. A.; Zhu, B.; Sheikh, S.; Hyde, R.; Deykin, A.; Sandrock, A.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Routine Laboratory Measures in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis
Wolinsky, Jerry; Kappos, Ludwig; Montalban, Xavier; Chognot, Cathy; Koendgen, Harold; Li, Carrie; Pradhan, Ashish; Hauser, Stephen. Neurology. 2018.Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser, Stephen; Kappos, Ludwig; Montalban, Xavier; Koendgen, Harold; Li, Carrie; Marcillat, Carole; Pradhan, Ashish; Wormser, David; Wolinsky, Jerry. Neurology. 2018.Safety of Ozanimod Versus Interferon beta-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B)
Cree, Bruce; Bar-Or, Amit; Comi, Giancarlo; Selmaj, Krzysztof; Arnold, Douglas; Steinman, Lawrence; Hartung, Hans-Peter; Montalban, Xavier; Havrdova, Eva; Sheffield, James; Raghupathi, Kartik; Kappos, Ludwig; Cohen, Jeffrey. Neurology. 2018.Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J. Brain : a journal of neurology. 2018.Serum neurofilament light (NfL) for disease prognosis and treatment monitoring in multiple sclerosis patients: is it ready for implementation into clinical care?.
Calabresi, P.; Kuhle, J.; Arnold, D. L.; Singh, C. M.; Kinkel, R. P.; Kappos, L.; Sangurdekar, D.; de Moor, C.; Engle, B.; Su, R.; Deykin, A.; Fisher, E.; Sandrock, A.; Kieseier, B. C.; Rudick, R. A.; Plavina, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Serum neurofilament light chain correlates with cortical lesion load at 3T and 7T in early RRMS patients
Lu, P. -J.; Fartaria, M. J.; Yaldizli, O.; Kappos, L.; Barro, C.; Kuhle, J.; Granziera, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T. Multiple sclerosis and related disorders. 2018.Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients
Kuhle, Jens; Kropshofer, Harald; Barro, Christian; Meinert, Rolf; Haring, Dieter A.; Leppert, David; Tomic, Davorka; Dahlke, Frank; Kappos, Ludwig. Neurology. 2018.Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos L.; Bar-Or A.; Cree B.A.C.; Fox R.J.; Giovannoni G.; Gold R.; Vermersch P.; Arnold D.L.; Arnould S.; Scherz T.; Wolf C.; Wallstrom E.; Dahlke F.; Achiron A.; Achtnichts L.; Agan K.; Akman-Demir G.; Allen A.B.; Antel J.P.; Antiguedad A.R.; Apperson M.; Applebee A.M.; Ayuso G.I.; Baba M.; Bajenaru O.; Balasa R.; Balci B.P.; Barnett M.; Bass A.; Becker V.U.; Bejinariu M.; Bergh F.T.; Bergmann A.; Bernitsas E.; Berthele A.; Bhan V.; Bischof F.; Bjork R.J.; Blevins G.; Boehringer M.; Boerner T.; Bonek R.; Bowen J.D.; Bowling A.; Boyko A.N.; Boz C.; Bracknies V.; Braune S.; Brescia Morra V.; Brochet B.; Brola W.; Brownstone P.K.; Brozman M.; Brunet D.; Buraga I.; Burnett M.; Buttmann M.; Butzkueven H.; Cahill J.; Calkwood J.C.; Camu W.; Cascione M.; Castelnovo G.; Centonze D.; Cerqueira J.; Chan A.; Cimprichova A.; Cohan S.; Comi G.; Conway J.; Cooper J.A.; Corboy J.; Correale J.; Costell B.; Cottrell D.A.; Coyle P.K.; Craner M.; Cui L.; Cunha L.; Czlonkowska A.; da Silva A.M.; de Sa J.; de Seze J.; Debouverie M.; Debruyne J.; Decoo D.; Defer G.; Derfuss T.; Deri N.H.; Dihenia B.; Dioszeghy P.; Donath V.; Dubois B.; Duddy M.; Duquette P.; Edan G.; Efendi H.; Elias S.; Emrich P.J.; Estruch B.C.; Evdoshenko E.P.; Faiss J.; Fedyanin A.S.; Feneberg W.; Fermont J.; Fernandez O.F.; Ferrer F.C.; Fink K.; Ford H.; Ford C.; Francia A.; Freedman M.; Frishberg B.; Galgani S.; Garmany G.P.; Gehring K.; Gitt J.; Gobbi C.; Goldstick L.P.; Gonzalez R.A.; Grandmaison F.; Grigoriadis N.; Grigorova O.; Grimaldi L.M.E.; Gross J.; Gross-Paju K.; Gudesblatt M.; Guillaume D.; Haas J.; Hancinova V.; Hancu A.; Hardiman O.; Harmjanz A.; Heidenreich F.R.; Hengstman G.J.D.; Herbert J.; Herring M.; Hodgkinson S.; Hoffmann O.M.; Hofmann W.E.; Honeycutt W.D.; Hua L.H.; Huang D.; Huang Y.; Huang D.; Hupperts R.; Imre P.; Jacobs A.K.; Jakab G.; Jasinska E.; Kaida K.; Kalnina J.; Kaprelyan A.; Karelis G.; Karussis D.; Katz A.; Khabirov F.A.; Khatri B.; Kimura T.; Kister I.; Kizlaitiene R.; Klimova E.; Koehler J.; Komatineni A.; Kornhuber A.; Kovacs K.; Koves A.; Kozubski W.; Krastev G.; Krupp L.B.; Kurca E.; Lassek C.; Laureys G.; Lee L.; Lensch E.; Leutmezer F.; Li H.; Linker R.A.; Linnebank M.; Liskova P.; Llanera C.; Lu J.; Lutterotti A.; Lycke J.; Macdonell R.; Maciejowski M.; Maeurer M.; Magzhanov R.V.; Maida E.-M.; Malciene L.; Mao-Draayer Y.; Marfia G.A.; Markowitz C.; Mastorodimos V.; Matyas K.; Meca-Lallana J.; Merino J.A.G.; Mihetiu I.G.; Milanov I.; Miller A.E.; Millers A.; Mirabella M.; Mizuno M.; Montalban X.; Montoya L.; Mori M.; Mueller S.; Nakahara J.; Nakatsuji Y.; Newsome S.; Nicholas R.; Nielsen A.S.; Nikfekr E.; Nocentini U.; Nohara C.; Nomura K.; Odinak M.M.; Olsson T.; van Oosten B.W.; Oreja-Guevara C.; Oschmann P.; Overell J.; Pachner A.; Panczel G.; Pandolfo M.; Papeix C.; Patrucco L.; Pelletier J.; Piedrabuena R.; Pless M.; Polzer U.; Pozsegovits K.; Rastenyte D.; Rauer S.; Reifschneider G.; Rey R.; Rizvi S.A.; Robertson D.; Rodriguez J.M.; Rog D.; Roshanisefat H.; Rowe V.; Rozsa C.; Rubin S.; Rusek S.; Sacca F.; Saida T.; Salgado A.V.; Sanchez V.E.F.; Sanders K.; Satori M.; Sazonov D.V.; Scarpini E.A.; Schlegel E.; Schluep M.; Schmidt S.; Scholz E.; Schrijver H.M.; Schwab M.; Schwartz R.; Scott J.; Selmaj K.; Shafer S.; Sharrack B.; Shchukin I.A.; Shimizu Y.; Shotekov P.; Siever A.; Sigel K.-O.; Silliman S.; Simo M.; Simu M.; Sinay V.; Siquier A.E.; Siva A.; Skoda O.; Solomon A.; Stangel M.; Stefoski D.; Steingo B.; Stolyarov I.D.; Stourac P.; Strassburger-Krogias K.; Strauss E.; Stuve O.; Tarnev I.; Tavernarakis A.; Tello C.R.; Terzi M.; Ticha V.; Ticmeanu M.; Tiel-Wilck K.; Toomsoo T.; Tubridy N.; Tullman M.J.; Tumani H.; Turcani P.; Turner B.; Uccelli A.; Urtaza F.J.O.; Vachova M.; Valikovics A.; Walter S.; Van Wijmeersch B.; Vanopdenbosch L.; Weber J.R.; Weiss S.; Weissert R.; Vermersch P.; West T.; Wiendl H.; Wiertlewski S.; Wildemann B.; Willekens B.; Visser L.H.; Vorobeychik G.; Xu X.; Yamamura T.; Yang Y.N.; Yelamos S.M.; Yeung M.; Zacharias A.; Zelkowitz M.; Zettl U.; Zhang M.; Zhou H.; Zieman U.; Ziemssen T.. The Lancet. 2018.Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (vol 391, pg 1263, 2018)
Kappos, L.; Bar-Or, A.; Cree, B. A. C.. The Lancet. 2018.Spinal cord volume loss: A marker of disease progression in multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K. Neurology. 2018.SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Bove R; Chitnis T; Cree BA; Tintoré M; Naegelin Y; Uitdehaag BM; Kappos L; Khoury SJ; Montalban X; Hauser SL; Weiner HL; SUMMIT Consortium. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.
Fernández O; Delvecchio M; Edan G; Fredrikson S; Giovannoni G; Hartung HP; Havrdova E; Kappos L; Pozzilli C; Soerensen PS; Tackenberg B; Vermersch P; Comi G. European journal of neurology. 2018.Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolisnky, J. S.; Brochet, B.; Montalban, X.; Naismith, R. T.; Manfrini, M.; Garas, M.; Villoslada, P.; Model, F.; Hubeaux, S.; Kappos, L.; Hauser, S. L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Temporal relationship of serum neurofilament light levels and radiological disease activity in patients with multiple sclerosis
Fox, R.; Cree, B. A. C.; De Seze, J.; Gold, R.; Hartung, H. -P.; Jeffery, D.; Kappos, L.; Montalban, X.; Weinstock-Guttman, B.; Singh, C. M.; Campbell, N.; Ho, P. -R.; Su, R.; Engle, B.; Sangurdekar, D.; de Moor, C.; Fisher, E.; Kieseier, B. C.; Rudick, R. A.; Plavina, T.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.The current role of MRI in differentiating multiple sclerosis from its imaging mimics.
Geraldes R; Ciccarelli O; Barkhof F; De Stefano N; Enzinger C; Filippi M; Hofer M; Paul F; Preziosa P; Rovira A; DeLuca GC; Kappos L; Yousry T; Fazekas F; Frederiksen J; Gasperini C; Sastre-Garriga J; Evangelou N; Palace J; MAGNIMS study group. Nature reviews. Neurology. 2018.The current role of MRI in differentiating multiple sclerosis from its imaging mimics.
Geraldes R; Ciccarelli O; Barkhof F; De Stefano N; Enzinger C; Filippi M; Hofer M; Paul F; Preziosa P; Rovira A; DeLuca GC; Kappos L; Yousry T; Fazekas F; Frederiksen J; Gasperini C; Sastre-Garriga J; Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group. Nature reviews. Neurology. 2018.The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Freedman MS; Wolinsky JS; Comi G; Kappos L; Olsson TP; Miller AE; Thangavelu K; Benamor M; Truffinet P; O'Connor PW; TEMSO and TOWER Study Groups. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.The hippocampus in multiple sclerosis
Rocca M.A.; Barkhof F.; De Luca J.; Frisén J.; Geurts J.J.G.; Hulst H.E.; Sastre-Garriga J.; Filippi M.; Ciccarelli O.; De Stefano N.; Enzinger C.; Frederiksen J.L.; Gasperini C.; Kappos L.; Palace J.; Rovira A.; Vrenken H.; Yousry T.A.. The Lancet Neurology. 2018.The POINT study: a randomized, double-blind, parallel-group, add-on, superiority phase 3 study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate
Kappos, L.; Lindenstrom, E.; Freedman, M.; Fox, R.; Havrdova, E.; Hennessy, B.; Hohlfeld, R.; Lemle, A.; Lublin, F.; Montalban, X.; Sprenger, T.; Pozzilli, C.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.The role of the cerebellum in multiple sclerosis-150 years after Charcot.
Parmar K; Stadelmann C; Rocca MA; Langdon D; D'Angelo E; D'Souza M; Burggraaff J; Wegner C; Sastre-Garriga J; Barrantes-Freer A; Dorn J; Uitdehaag BMJ; Montalban X; Wuerfel J; Enzinger C; Rovira A; Tintore M; Filippi M; Kappos L; Sprenger T; MAGNIMS study group. Neuroscience and biobehavioral reviews. 2018.Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials
Cohan, Stanley; Benedict, Ralph; De Seze, Jerome; Hauser, Stephen; Kappos, Ludwig; Wolinsky, Jerry; Julian, Laura; Villoslada, Pablo; Han, Jian; Pradhan, Ashish; Miller, Aaron. Neurology. 2018.Time to relapse is comparable in pediatric-and adult-onset multiple sclerosis patients after the initiation of disease-modifying therapy
Decard, B. F.; von Wyl, V.; Benkert, P.; Lorscheider, J.; Hanni, P.; Lienert, C.; Kuhle, J.; Derfuss, T.; Kappos, L.; Yaldizli, O.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
Kappos L; Arnold DL; Bar-Or A; Camm AJ; Derfuss T; Sprenger T; Davies M; Piotrowska A; Ni P; Harada T. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study
Cree, Bruce; Fox, Robert; Giovannoni, Gavin; Vermersch, Patrick; Bar-Or, Amit; Gold, Ralf; Magnusson, Baldur; Rouyrre, Nicolas; Meier, Daniela Piani; Tomic, Davorka; Karlsson, Goeril; Dahlke, Frank; Kappos, Ludwig. Neurology. 2018.Upper extremity function and its relation with ambulatory impairment in multiple sclerosis
van Munster, C. E. P.; Burggraaff, J.; Steinheimer, S.; Kamm, C. P.; D'Souza, M.; Boisvert, J.; Diederich, M.; Kravalis, K.; Dorn, J.; Walsh, L.; Balk, L.; Dahlke, F.; Kappos, L.; Uitdehaag, B. M. J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Validation of brain atrophy measurements in multiple sclerosis: a physical phantom study
Altermatt, A.; Santini, F.; Deligianni, X.; Magon, S.; Sprenger, T.; Kappos, L.; Cattin, P.; Wuerfel, J.; Gaetano, L.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Value of serum neurofilament light chain levels as a biomarker of suboptimal treatment response in MS clinical practice.
Yaldizli, O.; Barro, C.; Michalak, Z.; Vehoff, J.; Lascano, A. M.; Disanto, G.; Salmen, A.; Derfuss, T.; Granziera, C.; Achtnichts, L.; Findling, O.; Nedeltchev, K.; Kamm, C. P.; Pot, C.; Schluep, M.; Du Pasquier, R.; von Wyl, V.; Wuerfel, J.; Vallejo, V.; Chan, A.; Zecca, C.; Gobbi, C.; Lalive, P. H.; Mueller, S.; Kappos, L.; Benkert, P.; Kuhle, J.. Multiple sclerosis (Houndmills, Basingstoke, England). 2018.Cocapture of cognate and bystander antigens can activate autoreactive B cells.
Sanderson NS; Zimmermann M; Eilinger L; Gubser C; Schaeren-Wiemers N; Lindberg RL; Dougan SK; Ploegh HL; Kappos L; Derfuss T. Proceedings of the National Academy of Sciences of the United States of America. 2017.Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ. Multiple sclerosis and related disorders. 2017.Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Sormani MP; Kappos L; Radue EW; Cohen J; Barkhof F; Sprenger T; Piani Meier D; Häring D; Tomic D; De Stefano N. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL. European journal of neurology. 2017.Fluid biomarker and electrophysiological outcome measures for progressive MS trials.
Barro C; Leocani L; Leppert D; Comi G; Kappos L; Kuhle J. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.INFUSION-RELATED REACTIONS WITH OCRELIZUMAB IN RMS AND PPMS
de Seze, Jerome; Bar-Or, Amit; Giovannoni, Gavin; Hemmer, Bernhard; Kappos, Ludwig; Lublin, Fred; Wolinsky, Jerry; Li, Carrie; Mairon, Nicole; Hauser, Stephen L.. Journal of neurology, neurosurgery, and psychiatry. 2017.Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.
Sørensen PS; Comi G; Vollmer TL; Montalban X; Kappos L; Dadon Y; Gorfine T; Margalit M; Sasson N; Rubinchick S; Knappertz V. International journal of MS care. 2017.Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors.
Kappos L. Neurology. 2017.Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.NEDA ACHIEVEMENT BY TIME INTERVAL WITH DACLIZUMAB
Giovannoni, Gavin; Kappos, Ludwig; Havrdova, Eva; Khatri, Bhupendra O.; Gauthier, Susan A.; Greenberg, Steven J.; Wang, Ping; Giannattasio, Giorgio. Journal of neurology, neurosurgery, and psychiatry. 2017.NEDA ANALYSIS BY EPOCH IN THE OPERA STUDIES OF OCRELIZUMAB
Giovannoni, Gavin; Arnold, Douglas L.; Bar-Or, Amit; Havrdova, Eva; Kappos, Ludwig; Lublin, Fred; Traboulsee, Anthony; Belachew, Shibeshih; Han, Jian; Hauser, Stephen L.. Journal of neurology, neurosurgery, and psychiatry. 2017.Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
D'Souza M; Yaldizli Ö; John R; Vogt DR; Papadopoulou A; Lucassen E; Menegola M; Andelova M; Dahlke F; Schnyder F; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Kappos L; Havrdova E; Giovannoni G; Khatri BO; Gauthier SA; Greenberg SJ; You X; Wang P; Giannattasio G. Multiple sclerosis (Houndmills, Basingstoke, England). 2017.Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
Hauser SL; Belachew S; Kappos L. The New England journal of medicine. 2017.Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L; OPERA I and OPERA II Clinical Investigators. The New England journal of medicine. 2017.Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS; ORATORIO Clinical Investigators.. The New England journal of medicine. 2017.Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.
de Sitter A; Steenwijk MD; Ruet A; Versteeg A; Liu Y; van Schijndel RA; Pouwels PJW; Kilsdonk ID; Cover KS; van Dijk BW; Ropele S; Rocca MA; Yiannakas M; Wattjes MP; Damangir S; Frisoni GB; Sastre-Garriga J; Rovira A; Enzinger C; Filippi M; Frederiksen J; Ciccarelli O; Kappos L; Barkhof F; Vrenken H; MAGNIMS study group and for neuGRID. NeuroImage. 2017.PML risk and natalizumab: the elephant in the room
Derfuss T.; Kappos L.. The Lancet Neurology. 2017.Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC. Neurology. 2017.Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J; Swiss Multiple Sclerosis Cohort Study Group. Annals of neurology. 2017.Sodium intake and multiple sclerosis activity and progression in BENEFIT.
Fitzgerald KC; Munger KL; Hartung HP; Freedman MS; Montalbán X; Edan G; Wicklein EM; Radue EW; Kappos L; Pohl C; Ascherio A; BENEFIT Study Group. Annals of neurology. 2017.Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.
Comi G; De Stefano N; Freedman MS; Barkhof F; Uitdehaag BM; de Vos M; Marhardt K; Chen L; Issard D; Kappos L. Journal of neurology, neurosurgery, and psychiatry. 2017.Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.
Traboulsee A; Li D; Tam R; Zhao G; Riddehough A; Fang J; Dangond F; Kappos L; PRISMS and SPECTRIMS Working Groups. Multiple sclerosis journal - experimental, translational and clinical. 2017.Survey of diagnostic and treatment practices for multiple sclerosis in Europe.
Fernández O; Delvecchio M; Edan G; Fredrikson S; Gionvannoni G; Hartung HP; Havrdova E; Kappos L; Pozzilli C; Soerensen PS; Tackenberg B; Vermersch P; Comi G. European journal of neurology. 2017.Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.
Radue EW; Sprenger T; Gaetano L; Mueller-Lenke N; Cavalier S; Thangavelu K; Panzara MA; Donaldson JE; Woodward FM; Wuerfel J; Wolinsky JS; Kappos L. Neurology(R) neuroimmunology & neuroinflammation. 2017.α4-integrin receptor desaturation and disease activity return after natalizumab cessation.
Derfuss T; Kovarik JM; Kappos L; Savelieva M; Chhabra R; Thakur A; Zhang Y; Wiendl H; Tomic D. Neurology(R) neuroimmunology & neuroinflammation. 2017.[Cell depletion and myoablation for neuroimmunological diseases].
Diebold M; Kappos L; Derfuss T. Der Nervenarzt. 2016.A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.
Collins CD; Ivry B; Bowen JD; Cheng EM; Dobson R; Goodin DS; Lechner-Scott J; Kappos L; Galea I. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Assessing Multiple Sclerosis With Kinect: Designing Computer Vision Systems for Real-World Use
Morrison C.; Huckvale K.; Corish B.; Dorn J.; Kontschieder P.; O’Hara K.; Criminisi A.; Sellen A.; Dahlke F.; Kappos L.; Uitdehaag B.; Burggraaff J.; Kamm C.; Steinheimer S.; D’Souza M.. HUMAN-COMPUTER INTERACTION. 2016.Assessing response to interferon-β in a multicenter dataset of patients with MS.
Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N; MAGNIMS study group. Neurology. 2016.Automatic segmentation of plaque and four-dimensional analysis of magnetic resonance images used in the diagnosis and disease monitoring of multiple sclerosis
Demir, S.; Bayram, B.; Demir, N.; Catal, H.; Togrol, R. E.; Kafadar, C.; Ozdag, M. F.. Schw Arch fuer Neurol und Psych. 2016.Brain Volume as a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial
Wolinsky, Jerry; Haring, Dieter; Sormani, Maria Pia; Lublin, Fred; Miller, David; Freedman, Mark; Cree, Bruce; Weiner, Howard; Lubetzki, Catherine; Hartung, Hans-Peter; Montalban, Xavier; Uitdehaag, Bernard; Merschhemke, Martin; Li, Bingbing; Pulzki, Norman; Kappos, Ludwig. Neurology. 2016.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Spelman T; Kalincik T; Jokubaitis V; Zhang A; Pellegrini F; Wiendl H; Belachew S; Hyde R; Verheul F; Lugaresi A; Havrdová E; Horáková D; Grammond P; Duquette P; Prat A; Iuliano G; Terzi M; Izquierdo G; Hupperts RM; Boz C; Pucci E; Giuliani G; Sola P; Spitaleri DL; Lechner-Scott J; Bergamaschi R; Grand'Maison F; Granella F; Kappos L; Trojano M; Butzkueven H. Neurology. Clinical practice. 2016.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Spelman T; Kalincik T; Jokubaitis V; Zhang A; Pellegrini F; Wiendl H; Belachew S; Hyde R; Verheul F; Lugaresi A; Havrdová E; Horáková D; Grammond P; Duquette P; Prat A; Iuliano G; Terzi M; Izquierdo G; Hupperts RM; Boz C; Pucci E; Giuliani G; Sola P; Spitaleri DL; Lechner-Scott J; Bergamaschi R; Grand'Maison F; Granella F; Kappos L; Trojano M; Butzkueven H. Neurology. Clinical practice. 2016.Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.
Giovannoni G; Gold R; Kappos L; Arnold DL; Bar-Or A; Marantz JL; Yang M; Lee A. Multiple sclerosis journal - experimental, translational and clinical. 2016.Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients With Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-blind, Double-dummy, Interferon Beta-1a-controlled OPERA I and OPERA II Studies
Gobbi, C.; Arnold, D. L.; Bar-Or, A.; Hartung, H. P.; Hauser, S. L.; Lublin, F.; Selmaj, K.; Traboulsee, A. L.; Klingelschmitt, G.; Masterman, D.; Fontoura, P.; Chin, P.; Garren, H.; Wolinsky, J.; Kappos, L.. Swiss Medical Weekly. 2016.Efficacy and Safety of Fingolimod in an Unselected Patient Population.
Rasenack M; Rychen J; Andelova M; Naegelin Y; Stippich C; Kappos L; Lindberg RL; Sprenger T; Derfuss T. PLoS One. 2016.Efficacy of Ocrelizumab in Patients With Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-blind, Double-dummy, Interferon Beta-1a-controlled Studies
Derfuss, T.; Hauser, S. L.; Arnold, D. L.; Bar-Or, A.; Hartung, H. P.; Lublin, F.; Selmaj, K.; Traboulsee, A. L.; Klingelschmitt, G.; Masterman, D.; Fontoura, P.; Chin, P.; Garren, H.; Kappos, L.. . 2016.Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S; Tysabri® Observational Program (TOP) Investigators. PLoS One. 2016.Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.
Schippling S; O'Connor P; Knappertz V; Pohl C; Bogumil T; Suarez G; Cook S; Filippi M; Hartung HP; Comi G; Jeffery DR; Kappos L; Goodin DS; Arnason B. Journal of Neurology. 2016.Inclusion of brain volume loss in a revised measure of "no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Kappos, Ludwig; De Stefano, Nicola; Freedman, Mark S.; Cree, Bruce A. C.; Radue, Ernst-Wilhelm; Sprenger, Till; Sormani, Maria Pia; Smith, Terence; Haring, Dieter A.; Meier, Daniela Piani; Tomic, Davorka. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study.
Fox J; Kraemer M; Schormann T; Dabringhaus A; Hirsch J; Eisele P; Szabo K; Weiss C; Amann M; Weier K; Naegelin Y; Kappos L; Gass A. International Journal of Molecular Sciences. 2016.Inflammatory Diseases of the Central and Peripheral Nervous System in Patients with Systemic Lupus Erythematosus: Autoantibody Findings and Clinical Phenotype
Proebstel, Anne-Katrin; Thanai, Madlaina; Erni, Barbara; Anne-Catherine, Lecourt; Branco, Leonore; Ribi, Camillo; Koenig, Katrin; Huynh-Do, Uyen; Chizzolini, Carlo; Kappos, Ludwig; Trendelenburg, Marten; Derfuss, Tobias. Neurology. 2016.Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.
Havla J; Warnke C; Derfuss T; Kappos L; Hartung HP; Hohlfeld R. Deutsches Arzteblatt International. 2016.Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
Cohen JA; Khatri B; Barkhof F; Comi G; Hartung HP; Montalban X; Pelletier J; Stites T; Ritter S; von Rosenstiel P; Tomic D; Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Journal of neurology, neurosurgery, and psychiatry. 2016.Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
. Neurology. 2016.Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas. Neurology. 2016.Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic.
Pröbstel AK; Schaller A; Lieb J; Hench J; Frank S; Fuhr P; Kappos L; Sinnreich M. Neurology-Genetics. 2016.Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems.
Schlaeger R; Hardmeier M; D'Souza M; Grize L; Schindler C; Kappos L; Fuhr P. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2016.MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Filippi, Massimo; Rocca, Maria A.; Ciccarelli, Olga; De Stefano, Nicola; Evangelou, Nikos; Kappos, Ludwig; Rovira, Alex; Sastre-Garriga, Jaume; Tintore, Mar; Frederiksen, Jette L.; Gasperini, Claudio; Palace, Jacqueline; Reich, Daniel S.; Banwell, Brenda; Montalban, Xavier; Barkhof, Frederik. The Lancet Neurology. 2016.Multiple Sclerosis and Antibodies against KIR4.1.
Pröbstel AK; Kuhle J; Lecourt AC; Vock I; Sanderson NS; Kappos L; Derfuss T. The New England journal of medicine. 2016.Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.
Mäurer M; Comi G; Freedman MS; Kappos L; Olsson TP; Wolinsky JS; Miller AE; Dive-Pouletty C; Bozzi S; O'Connor PW. Multiple sclerosis and related disorders. 2016.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Meira M; Sievers C; Hoffmann F; Haghikia A; Rasenack M; Décard BF; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Neurology(R) neuroimmunology & neuroinflammation. 2016.Neurofilament light chain level is a weak risk factor for the development of MS.
Arrambide G; Espejo C; Eixarch H; Villar LM; Alvarez-Cermeño JC; Picón C; Kuhle J; Disanto G; Kappos L; Sastre-Garriga J; Pareto D; Simon E; Comabella M; Río J; Nos C; Tur C; Castilló J; Vidal-Jordana A; Galán I; Arévalo MJ; Auger C; Rovira A; Montalban X; Tintore M. Neurology. 2016.Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
Kappos L; Radue EW; Chin P; Ritter S; Tomic D; Lublin F. Journal of Neurology. 2016.Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial
Lublin, Fred; Miller, David H; Freedman, Mark S; Cree, Bruce A C; Wolinsky, Jerry S; Weiner, Howard; Lubetzki, Catherine; Hartung, Hans-Peter; Montalban, Xavier; Uitdehaag, Bernard M J; Merschhemke, Martin; Li, Bingbing; Putzki, Norman; Liu, Fonda C; Häring, Dieter A; Kappos, Ludwig; INFORMS study investigators. The Lancet. 2016.Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial
Lublin, Fred; Miller, David H; Freedman, Mark S; Cree, Bruce A C; Wolinsky, Jerry S; Weiner, Howard; Lubetzki, Catherine; Hartung, Hans-Peter; Montalban, Xavier; Uitdehaag, Bernard M J; Merschhemke, Martin; Li, Bingbing; Putzki, Norman; Liu, Fonda C; Häring, Dieter A; Kappos, Ludwig; INFORMS study investigators. The Lancet. 2016.Periodic alternating nystagmus in a patient on long-term lithium medication.
Rust H; Lutz N; Honegger F; Fischer-Barnicol D; Welge-Luessen A; Kappos L; Allum JHJ. Journal of the neurological sciences. 2016.Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP. Multiple sclerosis and related disorders. 2016.Power estimation for non-standardized multisite studies.
Keshavan A; Paul F; Beyer MK; Zhu AH; Papinutto N; Shinohara RT; Stern W; Amann M; Bakshi R; Bischof A; Carriero A; Comabella M; Crane JC; D'Alfonso S; Demaerel P; Dubois B; Filippi M; Fleischer V; Fontaine B; Gaetano L; Goris A; Graetz C; Gröger A; Groppa S; Hafler DA; Harbo HF; Hemmer B; Jordan K; Kappos L; Kirkish G; Llufriu S; Magon S; Martinelli-Boneschi F; McCauley JL; Montalban X; Mühlau M; Pelletier D; Pattany PM; Pericak-Vance M; Cournu-Rebeix I; Rocca MA; Rovira A; Schlaeger R; Saiz A; Sprenger T; Stecco A; Uitdehaag BMJ; Villoslada P; Wattjes MP; Weiner H; Wuerfel J; Zimmer C; Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG; Hauser SL; Oksenberg JR; Henry RG. NeuroImage. 2016.Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis.
Traboulsee AL; Cornelisseª P; Sandberg-Wollheim M; Uitdehaag BM; Kappos L; Jongen PJ; Constantinescu CS; di Cantogno EV; Li DK. Multiple sclerosis journal - experimental, translational and clinical. 2016.Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Amann M; Pezold S; Naegelin Y; Fundana K; Andělová M; Weier K; Stippich C; Kappos L; Radue EW; Cattin P; Sprenger T. Journal of Neurology. 2016.Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Kappos,Ludwig; Arnold,Douglas L; Bar-Or,Amit; Camm,John; Derfuss,Tobias; Kieseier,Bernd C; Sprenger,Till; Greenough,Kristin; Ni,Pingping; Harada,Tomohiko. The Lancet Neurology. 2016.Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Kappos,Ludwig; Arnold,Douglas L; Bar-Or,Amit; Camm,John; Derfuss,Tobias; Kieseier,Bernd C; Sprenger,Till; Greenough,Kristin; Ni,Pingping; Harada,Tomohiko. The Lancet Neurology. 2016.Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.
Kappos L; Li DK; Stüve O; Hartung HP; Freedman MS; Hemmer B; Rieckmann P; Montalban X; Ziemssen T; Hunter B; Arnould S; Wallström E; Selmaj K. JAMA neurology. 2016.Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
Giovannoni G; Kappos L; Gold R; Khatri BO; Selmaj K; Umans K; Greenberg SJ; Sweetser M; Elkins J; McCroskery P. Multiple sclerosis and related disorders. 2016.Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.
Disanto G; Adiutori R; Dobson R; Martinelli V; Dalla Costa G; Runia T; Evdoshenko E; Thouvenot E; Trojano M; Norgren N; Teunissen C; Kappos L; Giovannoni G; Kuhle J; International Clinically Isolated Syndrome Study Group. Journal of neurology, neurosurgery, and psychiatry. 2016.Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.
Rust H; Kuhle J; Kappos L; Derfuss T. Neurology-Neuroimmunology & Neuroinflammation. 2016.The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L; Edan G; Freedman MS; Montalbán X; Hartung HP; Hemmer B; Fox EJ; Barkhof F; Schippling S; Schulze A; Pleimes D; Pohl C; Sandbrink R; Suarez G; Wicklein EM; BENEFIT Study Group. Neurology. 2016.The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis
Yaldizli O.; Penner I.-K.; Yonekawa T.; Naegelin Y.; Kuhle J.; Pardini M.; Chard D.T.; Stippich C.; Kira J.-I.; Bendfeldt K.; Amann M.; Radue E.-W.; Kappos L.; Sprenger T.. European journal of neurology. 2016.The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V; MSBase study group. Multiple sclerosis (Houndmills, Basingstoke, England). 2016.The Swiss Multiple Sclerosis Cohort-Study (SMSC): A prospective Swiss wide investigation of key phases in disease evolution and new treatment options
Disanto G.; Benkert P.; Lorscheider J.; Mueller S.; Vehoff J.; Zecca C.; Ramseier S.; Achtnichts L.; Findling O.; Nedeltchev K.; Radue E.-W.; Sprenger T.; Stippich C.; Derfuss T.; Louvion J.-F.; Kamm C.P.; Mattle H.P.; Lotter C.; Du Pasquier R.; Schluep M.; Pot C.; Lalive P.H.; Yaldizli O.; Gobbi C.; Kappos L.; Kuhle J.; Saxer J.; Remonda L.; Boxheimer L.; Limberg M.; Scheerer I.; Orleth A.; Treppke F.; Beregi E.; Reinhardt J.; Fellner I.; Wurfel J.; Thoeni A.; Palatini A.; Pauli-Magnus C.; Fabbro T.; Roesler A.; Mechati S.; Chan A.; Salmen A.; Kaeser M.; Wagner F.; Verma R.; Di Marco M.; Haller S.; Lovblad K.-O.; Granziera C.; Hagmann P.; Maeder P.; Tschuor S.; Cianfoni A.; Weber J.. PLoS One. 2016.2015 Multiple Sclerosis Experts Summit.
Kappos L; Fazekas F. Neurodegenerative disease management. 2015.Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs
Gibbs E.; Karim M.E.; Oger J.; Edan G.; Freedman M.S.; Hartung H.P.; Kappos L.; Miller D.; Montalbán X.; Pleimes D.; Pohl C.; Polman C.; Sandbrink R.. Clinical immunology (Orlando, Fla.). 2015.Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T. Journal of neuroinflammation. 2015.A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH. Journal of neuroimmunology. 2015.A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis.
Freedman MS; Wolinsky JS; Truffinet P; Comi G; Kappos L; Miller AE; Olsson TP; Benamor M; Chambers S; O'Connor PW. Multiple sclerosis journal - experimental, translational and clinical. 2015.Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A. JAMA neurology. 2015.Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach.
Hubacher M; Kappos L; Weier K; Stöcklin M; Opwis K; Penner IK. Frontiers in neurology. 2015.Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.
Lukas C; Knol DL; Sombekke MH; Bellenberg B; Hahn HK; Popescu V; Weier K; Radue EW; Gass A; Kappos L; Naegelin Y; Uitdehaag BM; Geurts JJ; Barkhof F; Vrenken H. Journal of neurology, neurosurgery, and psychiatry. 2015.Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M. Brain : a journal of neurology. 2015.Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity.
Hubacher M; DeLuca J; Weber P; Steinlin M; Kappos L; Opwis K; Penner IK. RESTORATIVE NEUROLOGY AND NEUROSCIENCE. 2015.Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Spelman T; Kalincik T; Zhang A; Pellegrini F; Wiendl H; Kappos L; Tsvetkova L; Belachew S; Hyde R; Verheul F; Grand-Maison F; Izquierdo G; Grammond P; Duquette P; Lugaresi A; Lechner-Scott J; Oreja-Guevara C; Hupperts R; Petersen T; Barnett M; Trojano M; Butzkueven H. Annals of Clinical and Translational Neurology. 2015.Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations.
Amann M; Sprenger T; Naegelin Y; Reinhardt J; Kuster P; Hirsch JG; Kappos L; Radue EW; Stippich C; Bieri O. NeuroImage. 2015.Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.
Kuhle J; Disanto G; Dobson R; Adiutori R; Bianchi L; Topping J; Bestwick JP; Meier UC; Marta M; Dalla Costa G; Runia T; Evdoshenko E; Lazareva N; Thouvenot E; Iaffaldano P; Direnzo V; Khademi M; Piehl F; Comabella M; Sombekke M; Killestein J; Hegen H; Rauch S; D'Alfonso S; Alvarez-Cermeño JC; Kleinová P; Horáková D; Roesler R; Lauda F; Llufriu S; Avsar T; Uygunoglu U; Altintas A; Saip S; Menge T; Rajda C; Bergamaschi R; Moll N; Khalil M; Marignier R; Dujmovic I; Larsson H; Malmestrom C; Scarpini E; Fenoglio C; Wergeland S; Laroni A; Annibali V; Romano S; Martínez AD; Carra A; Salvetti M; Uccelli A; Torkildsen Ø; Myhr KM; Galimberti D; Rejdak K; Lycke J; Frederiksen JL; Drulovic J; Confavreux C; Brassat D; Enzinger C; Fuchs S; Bosca I; Pelletier J; Picard C; Colombo E; Franciotta D; Derfuss T; Lindberg R; Yaldizli Ö; Vécsei L; Kieseier BC; Hartung HP; Villoslada P; Siva A; Saiz A; Tumani H; Havrdová E; Villar LM; Leone M; Barizzone N; Deisenhammer F; Teunissen C; Montalban X; Tintoré M; Olsson T; Trojano M; Lehmann S; Castelnovo G; Lapin S; Hintzen R; Kappos L; Furlan R; Martinelli V; Comi G; Ramagopalan SV; Giovannoni G. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
Radue EW; Barkhof F; Kappos L; Sprenger T; Häring DA; de Vera A; von Rosenstiel P; Bright JR; Francis G; Cohen JA. Neurology. 2015.Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J. The New England journal of medicine. 2015.Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Gold R; Phillips JT; Havrdova E; Bar-Or A; Kappos L; Kim N; Thullen T; Valencia P; Oliva L; Novas M; Li J; Sweetser MT; Kurukulasuriya N; Viglietta V; Fox RJ. Neurology and Therapy. 2015.Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Rovira À; Wattjes MP; Tintoré M; Tur C; Yousry TA; Sormani MP; De Stefano N; Filippi M; Auger C; Rocca MA; Barkhof F; Fazekas F; Kappos L; Polman C; Miller D; Montalban X; MAGNIMS study group. Nature reviews. Neurology. 2015.Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
Wattjes MP; Rovira À; Miller D; Yousry TA; Sormani MP; de Stefano MP; Tintoré M; Auger C; Tur C; Filippi M; Rocca MA; Fazekas F; Kappos L; Polman C; Frederik Barkhof; Xavier Montalban; MAGNIMS study group. Nature reviews. Neurology. 2015.Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM. Journal of neurology, neurosurgery, and psychiatry. 2015.Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L. Neurology. 2015.Fingolimod effect on brain volume loss independently contributes to its effect on disability.
Sormani MP; De Stefano N; Francis G; Sprenger T; Chin P; Radue EW; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
Zimmermann, Maria; Sanderson, Nicholas S. R.; Rasenack, Maria; Lalive, Patrice H.; Lang, Alois B.; Curtin, Francois; Lindberg, Raija L. P.; Kappos, Ludwig; Derfuss, Tobias. Neurology-Neuroimmunology & Neuroinflammation. 2015.In multiple sclerosis, use of fingolimod reduced immune responses to influenza and tetanus booster vaccines
Kappos L.; Absher J.R.; Neurology A.. Annals of internal medicine. 2015.Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Kappos L; O'Connor P; Radue EW; Polman C; Hohlfeld R; Selmaj K; Ritter S; Schlosshauer R; von Rosenstiel P; Zhang-Auberson L; Francis G. Neurology. 2015.Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L. Journal of Neurology. 2015.Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.
Amann M; Papadopoulou A; Andelova M; Magon S; Mueller-Lenke N; Naegelin Y; Stippich C; Radue EW; Bieri O; Kappos L; Sprenger T. Journal of Neurology. 2015.MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis.
Gass A; Rocca MA; Agosta F; Ciccarelli O; Chard D; Valsasina P; Brooks JC; Bischof A; Eisele P; Kappos L; Barkhof F; Filippi M; MAGNIMS Study Group. The Lancet Neurology. 2015.No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL; Fitzgerald KC; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Suarez G; Radue EW; Sandbrink R; Kappos L; Pohl C; Ascherio A. Neurology. 2015.No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL; Fitzgerald KC; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Suarez G; Radue EW; Sandbrink R; Kappos L; Pohl C; Ascherio A. Neurology. 2015.Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.
Enzinger C; Barkhof F; Ciccarelli O; Filippi M; Kappos L; Rocca MA; Ropele S; Rovira À; Schneider T; de Stefano N; Vrenken H; Wheeler-Kingshott C; Wuerfel J; Fazekas F; MAGNIMS study group. Nature reviews. Neurology. 2015.On the origin of Neurostatus.
Kappos L; D'Souza M; Lechner-Scott J; Lienert C. Multiple sclerosis and related disorders. 2015.Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction
Zimmer A.; Blauer C.; Coslovsky M.; Kappos L.; Derfuss T.. Multiple sclerosis and related disorders. 2015.Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP; Kappos L; Goodin DS; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Petkau J; White R; Bogumil T; Beckmann K; Stemper B; Suarez G; Sandbrink R; Pohl C. Journal of Neurology. 2015.Quantified CSF antibody reactivity against myelin in multiple sclerosis.
Sun X; Bakhti M; Fitzner D; Schnaars M; Kruse N; Coskun Ü; Kremser C; Willecke K; Kappos L; Kuhle J; Simons M. Annals of Clinical and Translational Neurology. 2015.Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Kaufman M; Cree BA; De Sèze J; Fox RJ; Gold R; Hartung HP; Jeffery D; Kappos L; Montalbán X; Weinstock-Guttman B; Ticho B; Duda P; Pace A; Campagnolo D. Journal of Neurology. 2015.Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
Kappos L; Mehling M; Arroyo R; Izquierdo G; Selmaj K; Curovic-Perisic V; Keil A; Bijarnia M; Singh A; von Rosenstiel P. Neurology. 2015.Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E. CLINICAL THERAPEUTICS. 2015.Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T. Expert opinion on drug safety. 2015.Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome.
Kuhle J; Gaiottino J; Leppert D; Petzold A; Bestwick JP; Malaspina A; Lu CH; Dobson R; Disanto G; Norgren N; Nissim A; Kappos L; Hurlbert J; Yong VW; Giovannoni G; Casha S. Journal of neurology, neurosurgery, and psychiatry. 2015.Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).
Amann M; Andělová M; Pfister A; Mueller-Lenke N; Traud S; Reinhardt J; Magon S; Bendfeldt K; Kappos L; Radue EW; Stippich C; Sprenger T. NeuroImage. Clinical. 2015.Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Kappos L; Radue EW; Comi G; Montalban X; Butzkueven H; Wiendl H; Giovannoni G; Hartung HP; Derfuss T; Naegelin Y; Sprenger T; Mueller-Lenke N; Griffiths S; von Rosenstiel P; Gottschalk R; Zhang Y; Dahlke F; Tomic D; TOFINGO study group. Neurology. 2015.The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls.
Weier K; Eshaghi A; Magon S; Andelova M; Radue EW; Kappos L; Azimi AR; Sahraian MA; Sprenger T. Multiple sclerosis (Houndmills, Basingstoke, England). 2015.Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ; DEFINE and CONFIRM study investigators. European journal of neurology. 2015.Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade.
Mehling M; Burgener AV; Brinkmann V; Bantug GR; Dimeloe S; Hoenger G; Kappos L; Hess C. SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015.Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision.
Morrison C; D'Souza M; Huckvale K; Dorn JF; Burggraaff J; Kamm CP; Steinheimer SM; Kontschieder P; Criminisi A; Uitdehaag B; Dahlke F; Kappos L; Sellen A. JMIR human factors. 2015.Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N. JAMA neurology. 2015.What is new in MS spasticity research? Poster session highlights.
Kappos L; Fazekas F. Neurodegener Dis Manag. 2015.[Oral disease modifying therapy of multiple sclerosis: the current view].
Kappos L; Boĭko AN. ZH NEVROL PSIKHIATR. 2014.Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L; FIRST Study Investigators. Journal of Neurology. 2014.Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J; ATAMS Study Group. The Lancet Neurology. 2014.Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J; ATAMS Study Group. The Lancet Neurology. 2014.Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.
Kamm CP; El-Koussy M; Humpert S; Findling O; Burren Y; Schwegler G; Donati F; Müller M; Müller F; Slotboom J; Kappos L; Naegelin Y; Mattle HP; SWABIMS Study Group. PLoS One. 2014.Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS.
Mehling M; Eichin D; Hafner P; Hönger G; Kappos L; Hess C. Neurology(R) neuroimmunology & neuroinflammation. 2014.Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.
Weier K; Penner IK; Magon S; Amann M; Naegelin Y; Andelova M; Derfuss T; Stippich C; Radue EW; Kappos L; Sprenger T. PLoS One. 2014.Clinical trials in multiple sclerosis
Cutter, Gary; Kappos, Ludwig. Handbook of clinical neurology. 2014.Clinical trials in multiple sclerosis.
Cutter G; Kappos L. . 2014.Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years.
Schlaeger R; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Defining the clinical course of multiple sclerosis: the 2013 revisions.
Lublin FD; Reingold SC; Cohen JA; Cutter GR; Sørensen PS; Thompson AJ; Wolinsky JS; Balcer LJ; Banwell B; Barkhof F; Bebo B Jr; Calabresi PA; Clanet M; Comi G; Fox RJ; Freedman MS; Goodman AD; Inglese M; Kappos L; Kieseier BC; Lincoln JA; Lubetzki C; Miller AE; Montalban X; O'Connor PW; Petkau J; Pozzilli C; Rudick RA; Sormani MP; Stüve O; Waubant E; Polman CH. Neurology. 2014.Determinants of iron accumulation in deep grey matter of multiple sclerosis patients.
Ropele S; Kilsdonk ID; Wattjes MP; Langkammer C; de Graaf WL; Frederiksen JL; Larsson HB; Yiannakas M; Wheeler-Kingshott CA; Enzinger C; Khalil M; Rocca MA; Sprenger T; Amann M; Kappos L; Filippi M; Rovira A; Ciccarelli O; Barkhof F; Fazekas F. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).
Khatri BO; Pelletier J; Kappos L; Hartung HP; Comi G; Barkhof F; von Rosenstiel P; Meng X; Grinspan A; Hashmonay R; Cohen JA; TRANSFORMS Study Group. Multiple sclerosis and related disorders. 2014.Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L. CLINICAL THERAPEUTICS. 2014.Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT. Journal of Neurology. 2014.Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study.
Doerner M; Beckmann K; Knappertz V; Kappos L; Hartung HP; Filippi M; O'Connor PW; Arnason B; Cook S; Jeffery D; Comi G; Limmroth V. European Neurology. 2014.Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S; TYSABRI Observational Program (TOP) Investigators. Journal of neurology, neurosurgery, and psychiatry. 2014.Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F. Journal of neurology, neurosurgery, and psychiatry. 2014.Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.
Kappos L; Cohen J; Collins W; de Vera A; Zhang-Auberson L; Ritter S; von Rosenstiel P; Francis G. Multiple sclerosis and related disorders. 2014.First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.
DiMarco JP; O'Connor P; Cohen JA; Reder AT; Zhang-Auberson L; Tang D; Collins W; Kappos L. Multiple sclerosis and related disorders. 2014.Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
Kremenchutzky M; O'Connor P; Hohlfeld R; Zhang-Auberson L; von Rosenstiel P; Meng X; Grinspan A; Hashmonay R; Kappos L. Multiple sclerosis and related disorders. 2014.Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis.
Hardmeier M; Hatz F; Naegelin Y; Hight D; Schindler C; Kappos L; Seeck M; Michel CM; Fuhr P. BRAIN TOPOGRAPHY. 2014.Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome
Nagtegaal, Gijsbert J. A.; Pohl, Christoph; Wattjes, Mike P.; Hulst, Hanneke E.; Freedman, Mark S.; Hartung, Hans-Peter; Miller, David; Montalban, Xavier; Kappos, Ludwig; Edan, Gilles; Pleimes, Dirk; Beckman, Karola; Stemper, Brigitte; Polman, Christoph H.; Sandbrink, Rupert; Barkhof, Frederik. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability.
Magon S; Chakravarty MM; Amann M; Weier K; Naegelin Y; Andelova M; Radue EW; Stippich C; Lerch JP; Kappos L; Sprenger T. Human brain mapping. 2014.Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis.
Papadopoulou A; Menegola M; Kuhle J; Ramagopalan SV; D'Souza M; Sprenger T; Radue EW; Kappos L; Yaldizli Ö. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Edan G; Kappos L; Montalbán X; Polman CH; Freedman MS; Hartung HP; Miller D; Barkhof F; Herrmann J; Lanius V; Stemper B; Pohl C; Sandbrink R; Pleimes D; BENEFIT Study Group. Journal of neurology, neurosurgery, and psychiatry. 2014.Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P. Neurology. 2014.Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.
Kearney H; Rocca MA; Valsasina P; Balk L; Sastre-Garriga J; Reinhardt J; Ruggieri S; Rovira A; Stippich C; Kappos L; Sprenger T; Tortorella P; Rovaris M; Gasperini C; Montalban X; Geurts JJ; Polman CH; Barkhof F; Filippi M; Altmann DR; Ciccarelli O; Miller DH; Chard DT. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.
Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT. Journal of Neurology. 2014.MiR-126: a novel route for natalizumab action?
Meira M; Sievers C; Hoffmann F; Derfuss T; Kuhle J; Kappos L; Lindberg RL. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Munger KL; Köchert K; Simon KC; Kappos L; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Sandbrink R; Ascherio A; Pohl C. Annals of Clinical and Translational Neurology. 2014.Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.
Freedman MS; Comi G; De Stefano N; Barkhof F; Polman CH; Uitdehaag BM; Lehr L; Stubinski B; Kappos L. Multiple sclerosis and related disorders. 2014.MRI characteristics of periaqueductal lesions in multiple sclerosis.
Papadopoulou A; Naegelin Y; Weier K; Amann M; Hirsch J; von Felten S; Yaldizli O; Sprenger T; Radue EW; Kappos L; Gass A. Multiple sclerosis and related disorders. 2014.MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
Fox,Robert J; Cree,Bruce A C; De Sèze,Jerome; Gold,Ralf; Hartung,Hans-Peter; Jeffery,Douglas; Kappos,Ludwig; Kaufman,Michael; Montalbán,Xavier; Weinstock-Guttman,Bianca; Anderson,Britt; Natarajan,Amy; Ticho,Barry; Duda,Petra; RESTORE. Neurology. 2014.MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P; RESTORE. Neurology. 2014.Multicenter R2* mapping in the healthy brain.
Ropele S; Wattjes MP; Langkammer C; Kilsdonk ID; Graaf WL; Frederiksen JL; Fuglø D; Yiannakas M; Wheeler-Kingshott CA; Enzinger C; Rocca MA; Sprenger T; Amman M; Kappos L; Filippi M; Rovira A; Ciccarelli O; Barkhof F; Fazekas F. Magnetic Resonance in Medicine. 2014.Multiple sclerosis registries in Europe - results of a systematic survey.
Flachenecker P; Buckow K; Pugliatti M; Kes VB; Battaglia MA; Boyko A; Confavreux C; Ellenberger D; Eskic D; Ford D; Friede T; Fuge J; Glaser A; Hillert J; Holloway E; Ioannidou E; Kappos L; Kasilingam E; Koch-Henriksen N; Kuhle J; Lepore V; Middleton R; Myhr KM; Orologas A; Otero S; Pitschnau-Michel D; Rienhoff O; Sastre-Garriga J; Schyns-Liharska T; Sutovic D; Thalheim C; Trojano M; Vlasov YV; Yaldizli O; EUReMS Consortium. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW; TOPIC Study Group. The Lancet Neurology. 2014.Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial
Confavreux,Christian; O'Connor,Paul; Comi,Giancarlo; Freedman,Mark S; Miller,Aaron E; Olsson,Tomas P; Wolinsky,Jerry S; Bagulho,Teresa; Delhay,Jean-Luc; Dukovic,Deborah; Truffinet,Philippe; Kappos,Ludwig; TOWER Trial Group. The Lancet Neurology. 2014.Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.
Freedman MS; De Stefano N; Barkhof F; Polman CH; Comi G; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Lehr L; Stubinski B; Jack DL; Kappos L. Journal of Neurology. 2014.Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Filippi M; Rocca MA; Pagani E; De Stefano N; Jeffery D; Kappos L; Montalban X; Boyko AN; Comi G; ALLEGRO Study Group. Journal of neurology, neurosurgery, and psychiatry. 2014.Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval?
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2014.Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Karlsson G; Francis G; Koren G; Heining P; Zhang X; Cohen JA; Kappos L; Collins W. Neurology. 2014.Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis
Hofstetter L.; Naegelin Y.; Filli L.; Kuster P.; Traud S.; Smieskova R.; Mueller-Lenke N.; Kappos L.; Gass A.; Sprenger T.; Penner I.-K.; Nichols T.E.; Vrenken H.; Barkhof F.; Polman C.; Radue E.-W.; Borgwardt S.J.; Bendfeldt K.. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Quantifying progression of multiple sclerosis via classification of depth videos.
Kontschieder P; Dorn JF; Morrison C; Corish R; Zikic D; Sellen A; D'Souza M; Kamm CP; Burggraaff J; Tewarie P; Vogel T; Azzarito M; Glocker B; Chin P; Dahlke F; Polman C; Kappos L; Uitdehaag B; Criminisi A. Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention. 2014.Quantifying progression of multiple sclerosis via classification of depth videos.
Kontschieder P; Dorn JF; Morrison C; Corish R; Zikic D; Sellen A; D'Souza M; Kamm CP; Burggraaff J; Tewarie P; Vogel T; Azzarito M; Glocker B; Chin P; Dahlke F; Polman C; Kappos L; Uitdehaag B; Criminisi A. Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention. 2014.Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD. The Lancet Neurology. 2014.Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD. The Lancet Neurology. 2014.Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis.
Reder AT; Oger JF; Kappos L; O'Connor P; Rametta M. Multiple sclerosis and related disorders. 2014.Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Francis G; Kappos L; O'Connor P; Collins W; Tang D; Mercier F; Cohen JA. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.
Miller AE; Macdonell R; Comi G; Freedman MS; Kappos L; Mäurer M; Olsson TP; Wolinsky JS; Bozzi S; Dive-Pouletty C; O'Connor PW. Journal of Neurology. 2014.Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.
Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P; TENERE Trial Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients.
Yaldizli Ö; Penner IK; Frontzek K; Naegelin Y; Amann M; Papadopoulou A; Sprenger T; Kuhle J; Calabrese P; Radü EW; Kappos L; Gass A. Multiple sclerosis (Houndmills, Basingstoke, England). 2014.Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
Meira M; Sievers C; Hoffmann F; Rasenack M; Kuhle J; Derfuss T; Kappos L; Lindberg RL. Journal of Immunology Research. 2014.Vitamin D as an early predictor of multiple sclerosis activity and progression.
Ascherio A; Munger KL; White R; Köchert K; Simon KC; Polman CH; Freedman MS; Hartung HP; Miller DH; Montalbán X; Edan G; Barkhof F; Pleimes D; Radü EW; Sandbrink R; Kappos L; Pohl C. JAMA neurology. 2014.White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study.
Magon S; Gaetano L; Chakravarty MM; Lerch JP; Naegelin Y; Stippich C; Kappos L; Radue EW; Sprenger T. BMC NEUROSCIENCE. 2014.A comparative study of CSF neurofilament light and heavy chain protein in MS.
Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity.
Corporaal SH; Gensicke H; Kuhle J; Kappos L; Allum JH; Yaldizli Ö. Gait & posture. 2013.Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Kappos L; O'Connor PW; Polman CH; Vermersch P; Wiendl H; Pace A; Zhang A; Hotermans C. Journal of Neurology. 2013.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.
Bar-Or A; Gold R; Kappos L; Arnold DL; Giovannoni G; Selmaj K; O'Gorman J; Stephan M; Dawson KT. Journal of Neurology. 2013.Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
Papadopoulou A.; Muller-Lenke N.; Naegelin Y.; Kalt G.; Bendfeldt K.; Kuster P.; Stoecklin M.; Gass A.; Sprenger T.; Radue E.W.; Kappos L.; Penner I.-K.. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography.
Papadopoulou A; Ahlhelm FJ; Ulmer S; Kappos L; Sprenger T. JAMA neurology. 2013.Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Lampl C; Nagl S; Arnason B; Comi G; O Connor P; Cook S; Jeffery D; Kappos L; Filippi M; Beckmann K; Bogumil T; Pohl C; Sandbrink R; Hartung HP. Journal of Neurology. 2013.Global N-acetylaspartate concentration in benign and non-benignmultiple sclerosis patients of long disease duration
Achtnichts L.; Gonen O.; Rigotti D.J.; Babb J.S.; Naegelin Y.; Penner I.-K.; Bendfeldt K.; Hirsch J.; Amann M.; Kappos L.; Gass A.. European journal of radiology. 2013.Glutamate gene polymorphisms predict brain volumes in multiple sclerosis.
Strijbis EM; Inkster B; Vounou M; Naegelin Y; Kappos L; Radue EW; Matthews PM; Uitdehaag BM; Barkhof F; Polman CH; Montana G; Geurts JJ. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Inkster B; Strijbis EM; Vounou M; Kappos L; Radue EW; Matthews PM; Uitdehaag BM; Barkhof F; Polman CH; Montana G; Geurts JJ. Neurobiology of aging. 2013.Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.
Gaiottino J; Norgren N; Dobson R; Topping J; Nissim A; Malaspina A; Bestwick JP; Monsch AU; Regeniter A; Lindberg RL; Kappos L; Leppert D; Petzold A; Giovannoni G; Kuhle J. PLoS One. 2013.Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hartung HP; Steinman L; Goodin DS; Comi G; Cook S; Filippi M; O'Connor P; Jeffery DR; Kappos L; Axtell R; Knappertz V; Bogumil T; Schwenke S; Croze E; Sandbrink R; Pohl C. JAMA neurology. 2013.Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2013.Natalizumab therapy for multiple sclerosis.
Derfuss T; Kuhle J; Lindberg R; Kappos L. Seminars in Neurology. 2013.Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J. Acta neurologica Scandinavica. 2013.Predicting PML in natalizumab-treated patients: can we do better?
Derfuss T; Kappos L. Journal of neurology, neurosurgery, and psychiatry. 2013.Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy.
Mehling M; Fritz S; Hafner P; Eichin D; Yonekawa T; Klimkait T; Lindberg RL; Kappos L; Hess C. PLoS One. 2013.Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik S; Fraser G; Castets P; Schaeffer V; Skachokova Z; Breu K; Clavaguera F; Sinnreich M; Kappos L; Goedert M; Tolnay M; Winkler DT. PLoS One. 2013.Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study
Selmaj,Krzysztof; Li,David K B; Hartung,Hans-Peter; Hemmer,Bernhard; Kappos,Ludwig; Freedman,Mark S; Stüve,Olaf; Rieckmann,Peter; Montalban,Xavier; Ziemssen,Tjalf; Auberson,Lixin Zhang; Pohlmann,Harald; Mercier,Francois; Dahlke,Frank; Wallström,Erik. The Lancet Neurology. 2013.Six-year follow-up of a case series with non-communicating syringomyelia in multiple sclerosis.
Weier K; Naegelin Y; Amann M; Magon S; Mueller-Lenke N; Radue EW; Kappos L; Stippich C; Gass A; Sprenger T. European journal of neurology. 2013.T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin,Meret E; Lorscheider,Johannes; Waschbisch,Anne; Paroz,Cecile; Mehta,Satish K; Pierson,Duane L; Kuhle,Jens; Fischer-Barnicol,Bettina; Sprenger,Till; Lindberg,Raija L P; Kappos,Ludwig; Derfuss,Tobias. Neurology. 2013.Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
O'Connor PW; Lublin FD; Wolinsky JS; Confavreux C; Comi G; Freedman MS; Olsson TP; Miller AE; Dive-Pouletty C; Bégo-Le-Bagousse G; Kappos L. Journal of Neurology. 2013.3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS.
Amann M; Achtnichts L; Hirsch JG; Naegelin Y; Gregori J; Weier K; Thöni A; Mueller-Lenke N; Radue EW; Günther M; Kappos L; Gass A. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C. Journal of Neurology. 2012.Alemtuzumab for multiple sclerosis: who and when to treat?
Sprenger T; Kappos L. The Lancet. 2012.Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.
Sievers C; Meira M; Hoffmann F; Fontoura P; Kappos L; Lindberg RL. Clinical immunology (Orlando, Fla.). 2012.Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.
Kamm CP; El-Koussy M; Humpert S; Findling O; von Bredow F; Burren Y; Schwegler G; Schött D; Donati F; Müller M; Goebels N; Müller F; Slotboom J; Tettenborn B; Kappos L; Naegelin Y; Mattle HP. Journal of Neurology. 2012.Biplanar MRI for the assessment of the spinal cord in multiple sclerosis.
Weier K; Mazraeh J; Naegelin Y; Thoeni A; Hirsch JG; Fabbro T; Bruni N; Duyar H; Bendfeldt K; Radue EW; Kappos L; Gass A. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Combined evoked potentials as markers and predictors of disability in early multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2012.Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial
Comi,Giancarlo; De Stefano,Nicola; Freedman,Mark S; Barkhof,Frederik; Polman,Chris H; Uitdehaag,Bernard M J; Casset-Semanaz,Florence; Hennessy,Brian; Moraga,Margaretha Stam; Rocak,Sanda; Stubinski,Bettina; Kappos,Ludwig. The Lancet Neurology. 2012.Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Kappos L; Gold R; Miller DH; MacManus DG; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Eraksoy M; Meluzinova E; Dufek M; Yang M; Dawson K; O'Neill GN. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Penner IK; Stemper B; Calabrese P; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Pleimes D; Lanius V; Pohl C; Kappos L; Sandbrink R. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis.
Weier K; Beck A; Magon S; Amann M; Naegelin Y; Penner IK; Thürling M; Aurich V; Derfuss T; Radue EW; Stippich C; Kappos L; Timmann D; Sprenger T. Journal of Neurology. 2012.Evolution of MS lesions to black holes under DNA vaccine treatment.
Papadopoulou A; von Felten S; Traud S; Rahman A; Quan J; King R; Garren H; Steinman L; Cutter G; Kappos L; Radue EW. Journal of Neurology. 2012.Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Archives of Neurology. 2012.Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects.
Bendfeldt K; Hofstetter L; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Kappos L; Gass A; Nichols TE; Barkhof F; Vrenken H; Roosendaal SD; Geurts JJ; Radue EW; Borgwardt SJ. Human brain mapping. 2012.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.
Gensicke H; Leppert D; Yaldizli Ö; Lindberg RL; Mehling M; Kappos L; Kuhle J. CNS drugs. 2012.Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.
Rigotti DJ; Gass A; Achtnichts L; Inglese M; Babb JS; Naegelin Y; Hirsch J; Amann M; Kappos L; Gonen O. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Multivariate pattern classification of gray matter pathology in multiple sclerosis.
Bendfeldt K; Klöppel S; Nichols TE; Smieskova R; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Kappos L; Radue EW; Borgwardt SJ. NeuroImage. 2012.Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C; BEYOND Study Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Ocrelizumab in multiple sclerosis: risks and benefits (written by A. Chaudhuri) - Author’s reply
KAPPOS,L; LEPPERT,D; TIMMERMANN,J; GLANZMAN,R; HAUSER,S. . 2012.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT; DEFINE Study Investigators. The New England journal of medicine. 2012.Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G; Jeffery D; Kappos L; Montalban X; Boyko A; Rocca MA; Filippi M; ALLEGRO Study Group. The New England journal of medicine. 2012.Prediction of long-term disability in multiple sclerosis.
Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.
Freedman MS; Metzig C; Kappos L; Polman CH; Edan G; Hartung HP; Miller DH; Montalban X; Yarden J; Spector L; Fire E; Dotan N; Schwenke S; Lanius V; Sandbrink R; Pohl C. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS; Teriflunomide Multiple Sclerosis Trial Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
Devonshire,Virginia; Havrdova,Eva; Radue,Ernst Wilhelm; O'Connor,Paul; Zhang-Auberson,Lixin; Agoropoulou,Catherine; Häring,Dieter Adrian; Francis,Gordon; Kappos,Ludwig; FREEDOMS study group. The Lancet Neurology. 2012.Reporting of subgroup analyses from clinical trials - Author's reply
KAPPOS,L; DEVONSHIRE,V; HÄRING,DA. The Lancet Neurology. 2012.Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
Sorensen, Per Soelberg; Bertolotto, Antonio; Edan, Gilles; Giovannoni, Gavin; Gold, Ralf; Havrdova, Eva; Kappos, Ludwig; Kieseier, Bernd C.; Montalban, Xavier; Olsson, Tomas. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Screening for balance disorders in mildly affected multiple sclerosis patients.
Fanchamps MH; Gensicke H; Kuhle J; Kappos L; Allum JH; Yaldizli O. Journal of Neurology. 2012.Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis.
Filli L; Hofstetter L; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Kappos L; Gass A; Sprenger T; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K. Multiple sclerosis (Houndmills, Basingstoke, England). 2012.Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center. Neurology. 2012.Teriflunomide for oral therapy in multiple sclerosis.
Papadopoulou A; Kappos L; Sprenger T. Expert review of clinical pharmacology. 2012.Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
Hartung HP; Kieseier B; Goodin DS; Arnason BG; Comi G; Cook S; Filippi M; Jeffery DR; Kappos L; Bogumil T; Stemper B; Sandbrink R; Nakada Y; Nakajima H; Schwenke S; Lehr S; Heubach J; Pohl C; Reischl J. Journal of Neuroinflammation. 2012.A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility.
Bush WS; McCauley JL; DeJager PL; Dudek SM; Hafler DA; Gibson RA; Matthews PM; Kappos L; Naegelin Y; Polman CH; Hauser SL; Oksenberg J; Haines JL; Ritchie MD; International Multiple Sclerosis Genetics Consortium. GENES AND IMMUNITY. 2011.Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients.
Amann M; Dössegger LS; Penner IK; Hirsch JG; Raselli C; Calabrese P; Weier K; Radü EW; Kappos L; Gass A. Human brain mapping. 2011.Anterior pituitary axis hormones and outcome in acute ischaemic stroke
Neidert S.; Katan M.; Schuetz P.; Fluri F.; Ernst A.; Bingisser R.; Kappos L.; Engelter S.T.; Steck A.; Muller B.; Christ-Crain M.. Journal of Internal Medicine. 2011.Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
Mehling M; Hilbert P; Fritz S; Durovic B; Eichin D; Gasser O; Kuhle J; Klimkait T; Lindberg RL; Kappos L; Hess C. Annals of neurology. 2011.BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.
MacManus DG; Miller DH; Kappos L; Gold R; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Eraksoy M; Meluzinova E; Dufek M; Yang M; O'Neill GN; Dawson K. Journal of Neurology. 2011.Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
Acaster S; Swinburn P; Wang C; Stemper B; Beckmann K; Knappertz V; Pohl C; Sandbrink R; Gondek K; Edan G; Kappos L; Freedman M; Hartung HP; Arnason B; Comi G; Filippi M; Jeffery D; O'Connor P; Cook S; Lloyd AJ. Multiple sclerosis (Houndmills, Basingstoke, England). 2011.Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A. Neurology. 2011.Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.
Vermersch P; Kappos L; Gold R; Foley JF; Olsson T; Cadavid D; Bozic C; Richman S. Neurology. 2011.Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; TRANSFORMS Study Group. The Lancet Neurology. 2011.Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis.
Nielsen,Jessica M; Pohl,Christoph; Polman,Chris H; Barkhof,Frederik; Freedman,Mark S; Edan,Gilles; Miller,David H; Bauer,Lars; Sandbrink,Rupert; Kappos,Ludwig; Uitdehaag,Bernard Mj. BMC Neurology. 2011.Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Polman, Chris H.; Reingold, Stephen C.; Banwell, Brenda; Clanet, Michel; Cohen, Jeffrey A.; Filippi, Massimo; Fujihara, Kazuo; Havrdova, Eva; Hutchinson, Michael; Kappos, Ludwig; Lublin, Fred D.; Montalban, Xavier; O'Connor, Paul; Sandberg-Wollheim, Magnhild; Thompson, Alan J.; Waubant, Emmanuelle; Weinshenker, Brian; Wolinsky, Jerry S.. Annals of neurology. 2011.Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
O'Connor, P. W.; Goodman, A.; Kappos, L.; Lublin, F. D.; Miller, D. H.; Polman, C.; Rudick, R. A.; Aschenbach, W.; Lucas, N.. Neurology. 2011.Evaluation of soluble HLA-G as a biomarker for multiple sclerosis.
Waschbisch A; Sandbrink R; Hartung HP; Kappos L; Schwab S; Pohl C; Wiendl H. Neurology. 2011.Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Mehling M; Kappos L; Derfuss T. Current neurology and neuroscience reports. 2011.Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.
Rudick RA; Kappos L; Kinkel R; Clanet M; Phillips JT; Herndon RM; Sandrock AW; Munschauer FE 3rd. Multiple sclerosis (Houndmills, Basingstoke, England). 2011.Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium; Esposito F; Reischl J; Lehr S; Bauer D; Heubach J; Sandbrink R; Pohl C; Edan G; Kappos L; Miller D; Montalbán J; Polman CH; Freedman MS; Hartung HP; Arnason BG; Comi G; Cook S; Filippi M; Goodin DS; Jeffery D; O'Connor P; Ebers GC; Langdon D; Reder AT; Traboulsee A; Zipp F; Schimrigk S; Hillert J; Bahlo M; Booth DR; Broadley S; Brown MA; Browning BL; Browning SR; Butzkueven H; Carroll WM; Chapman C; Foote SJ; Griffiths L; Kermode AG; Kilpatrick TJ; Lechner-Scott J; Marriott M; Mason D; Moscato P; Heard RN; Pender MP; Perreau VM; Perera D; Rubio JP; Scott RJ; Slee M; Stankovich J; Stewart GJ; Taylor BV; Tubridy N; Willoughby E; Wiley J; Matthews P; Boneschi FM; Compston A; Haines J; Hauser SL; McCauley J; Ivinson A; Oksenberg JR; Pericak-Vance M; Sawcer SJ; De Jager PL; Hafler DA; de Bakker PI. Annals of neurology. 2011.Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.
Uitdehaag B; Constantinescu C; Cornelisse P; Jeffery D; Kappos L; Li D; Sandberg-Wollheim M; Traboulsee A; Verdun E; Rivera V. Therapeutic advances in neurological disorders. 2011.Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
Filippi M; Rocca MA; Camesasca F; Cook S; O'Connor P; Arnason BG; Kappos L; Goodin D; Jeffery D; Hartung HP; Comi G; Wolinsky JS; Bogumil T; Pohl C; Beckmann K; Sandbrink R; Croze E; Brown C; Desimone TM; Arnold DL; Cutter G; Knappertz V. Neurology. 2011.Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C; BENEFIT Study Group. Neurology. 2011.Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.
Kuhle J; Gosert R; Bühler R; Derfuss T; Sutter R; Yaldizli O; Radue EW; Ryschkewitsch C; Major EO; Kappos L; Frank S; Hirsch HH. Neurology. 2011.Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients
Osthoff M.; Katan M.; Fluri F.; Schuetz P.; Bingisser R.; Kappos L.; Steck A.J.; Engelter S.T.; Mueller B.; Christ-Crain M.; Trendelenburg M.. PLoS One. 2011.Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data.
Wang JH; Pappas D; De Jager PL; Pelletier D; de Bakker PI; Kappos L; Polman CH; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene); Chibnik LB; Hafler DA; Matthews PM; Hauser SL; Baranzini SE; Oksenberg JR. Genome Medicine. 2011.MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.
Barkhof F; Simon JH; Fazekas F; Rovaris M; Kappos L; de Stefano N; Polman CH; Petkau J; Radue EW; Sormani MP; Li DK; O'Connor P; Montalban X; Miller DH; Filippi M. Nature reviews. Neurology. 2011.Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Kappos L; Bates D; Edan G; Eraksoy M; Garcia-Merino A; Grigoriadis N; Hartung HP; Havrdová E; Hillert J; Hohlfeld R; Kremenchutzky M; Lyon-Caen O; Miller A; Pozzilli C; Ravnborg M; Saida T; Sindic C; Vass K; Clifford DB; Hauser S; Major EO; O'Connor PW; Weiner HL; Clanet M; Gold R; Hirsch HH; Radü EW; Sørensen PS; King J. The Lancet Neurology. 2011.Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL. Neurology. 2011.No influence of KIF1B on neurodegenerative markers in multiple sclerosis.
Sombekke MH; Jafari N; Bendfeldt K; Mueller-Lenke N; Radue EW; Naegelin Y; Kappos L; Matthews PM; Polman CH; Barkhof F; Hintzen R; Geurts JJ. Neurology. 2011.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL. The Lancet. 2011.Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Montalban X; Comi G; O'Connor P; Gold S; de Vera A; Eckert B; Kappos L. Multiple sclerosis (Houndmills, Basingstoke, England). 2011.Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS; TEMSO Trial Group. The New England journal of medicine. 2011.Stress hormones predict cerebrovascular re-events after transient ischemic attacks
Katan M.; Nigro N.; Fluri F.; Schuetz P.; Morgenthaler N.G.; Jax F.; Meckel S.; Gass A.; Bingisser R.; Steck A.; Kappos L.; Engelter S.; Muller B.; Christ-Crain M.. Neurology. 2011.A confusing patient's history: Small or large vessel vasculitis?
Cantoni N.; Meyer P.; Katan M.; Kappos L.; Hess C.; Daikeler T.. Rheumatology international. 2010.A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A. Journal of neuroimmunology. 2010.Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.
Lindberg RL; Hoffmann F; Mehling M; Kuhle J; Kappos L. European journal of immunology. 2010.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P; FREEDOMS Study Group. The New England journal of medicine. 2010.Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
Mesaros S; Rocca M; Sormani M; Valsasina P; Markowitz C; De Stefano N; Montalban X; Barkhof F; Ranjeva J; Sailer M; Kappos L; Comi G; Filippi M. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Black holes in multiple sclerosis: definition, evolution, and clinical correlations.
Sahraian MA; Radue EW; Haller S; Kappos L. Acta neurologica Scandinavica. 2010.Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis.
van den Elskamp IJ; Boden B; Dattola V; Knol DL; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F. Neuroradiology. 2010.Dimethyl fumarate for multiple sclerosis.
Papadopoulou A; D'Souza M; Kappos L; Yaldizli O. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2010.Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ. Brain research. 2010.Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.
Morrow SA; O'Connor PW; Polman CH; Goodman AD; Kappos L; Lublin FD; Rudick RA; Jurgensen S; Paes D; Forrestal F; Benedict RH. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Evidence for acute neurotoxicity after chemotherapy.
Petzold A; Mondria T; Kuhle J; Rocca MA; Cornelissen J; te Boekhorst P; Lowenberg B; Giovannoni G; Filippi M; Kappos L; Hintzen R. Annals of neurology. 2010.Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.
Jakkula E; Leppä V; Sulonen AM; Varilo T; Kallio S; Kemppinen A; Purcell S; Koivisto K; Tienari P; Sumelahti ML; Elovaara I; Pirttilä T; Reunanen M; Aromaa A; Oturai AB; Søndergaard HB; Harbo HF; Mero IL; Gabriel SB; Mirel DB; Hauser SL; Kappos L; Polman C; De Jager PL; Hafler DA; Daly MJ; Palotie A; Saarela J; Peltonen L. American Journal of Human Genetics. 2010.Images in clinical medicine. Dissociation of voluntary and emotional innervation after stroke.
Kappos L; Mehling M. The New England journal of medicine. 2010.Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.
Gilli F; Lindberg RL; Valentino P; Marnetto F; Malucchi S; Sala A; Capobianco M; di Sapio A; Sperli F; Kappos L; Calogero RA; Bertolotto A. PLoS One. 2010.Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis.
van den Elskamp IJ; Knol DL; Vrenken H; Karas G; Meijerman A; Filippi M; Kappos L; Fazekas F; Wagner K; Pohl C; Sandbrink R; Polman CH; Uitdehaag BM; Barkhof F. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Measuring disability in relapsing-remitting MS.
Rudick RA; Kappos L. Neurology. 2010.Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke
Katan M.; Fluri F.; Schuetz P.; Morgenthaler N.G.; Zweifel C.; Bingisser R.; Kappos L.; Steck A.; Engelter S.T.; Mller B.; Christ-Crain M.. Journal of the American College of Cardiology. 2010.MRI criteria for MS in patients with clinically isolated syndromes.
Montalban X; Tintoré M; Swanton J; Barkhof F; Fazekas F; Filippi M; Frederiksen J; Kappos L; Palace J; Polman C; Rovaris M; de Stefano N; Thompson A; Yousry T; Rovira A; Miller DH. Neurology. 2010.MR imaging in multiple sclerosis: review and recommendations for current practice.
Lövblad KO; Anzalone N; Dörfler A; Essig M; Hurwitz B; Kappos L; Lee SK; Filippi M. AJNR. American journal of neuroradiology. 2010.MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.
Grossman P; Kappos L; Gensicke H; D'Souza M; Mohr DC; Penner IK; Steiner C. Neurology. 2010.Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L; TRANSFORMS Study Group. The New England journal of medicine. 2010.Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L; FTY720D2201 Study Group. Multiple sclerosis (Houndmills, Basingstoke, England). 2010.Prognostic value of copeptin: One-year outcome in patients with acute stroke
Urwyler S.A.; Schuetz P.; Fluri F.; Morgenthaler N.G.; Zweifel C.; Bergmann A.; Bingisser R.; Kappos L.; Steck A.; Engelter S.; Muller B.; Christ-Crain M.; Katan M.. Stroke. 2010.Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis.
Bendfeldt K; Blumhagen JO; Egger H; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Hirsch J; Kappos L; Nichols TE; Radue EW; Borgwardt SJ. Human brain mapping. 2010.Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V. Neurology. 2010.[Stress-related vertical double vision and ptosis].
Palmowski-Wolfe AM; Kappos L; Müller-Brand J; Buitrago-Tellez C; Merlo A. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2009.250 microg or 500 microg interferon beta-1b v